Advertisements


Why a French biotech startup with diabetes "breakthrough" is basing operations out of Pittsburgh

By headquartering its U.S. operations in Pittsburgh, the startup will look to draw on all the resources in the region, including hiring dozens of people in the coming months to serve as consultants, suppliers and scientific advisors, among other roles......»»

Category: topSource: bizjournalsJan 25th, 2023

Lamb Weston (LW) Gains 25% in 3 Months: Will It Continue?

Lamb Weston (LW) is benefiting from the robust demand in the food away-from-home channels. The company's capacity expansion efforts are also impressive. Lamb Weston Holdings, Inc. LW is gaining on strategic growth efforts like boosting offerings and expanding capacity. The company has been benefiting from robust demand in the food away-from-home channels. In addition, its efficient price/mix is yielding well. Thanks to such upsides, Lamb Weston’s stock has gained 25.9% in the past three months compared with the industry’s growth of 6.1%.Let’s delve deeper.Away-From-Home Demand SolidLamb Weston is gaining from strong demand for away-from-home frozen potato products. Such trends contributed to the top line in second-quarter fiscal 2022, wherein net sales amounted to $1,007 million, up 12% year over year. Volume increased 6%, driven by the ongoing recovery in demand for frozen potato products in its restaurant and foodservice channels across North America.Speaking of segments, volumes rose 4% in the Global unit, driven by solid growth in shipments to restaurant chain customers across the United States. Foodservice volumes increased 22%, driven by the solid demand at small and regional chain restaurants combined with independently owned restaurants. For fiscal 2022, management expects net sales growth to exceed its long-term goal of low to mid-single digits. Image Source: Zacks Investment Research Other DriversLamb Weston’s top line has been benefiting from a robust price/mix, as witnessed in the second quarter of fiscal 2022. In the quarter, price/mix went up 6% on the back of initial benefits from product pricing actions along with better prices charged to customers for product delivery.For the second half of fiscal 2022, the company expects net sales growth to be mainly driven by price/mix. For the fiscal third quarter, management anticipates the price mix to improve sequentially, owing to benefits from the earlier announced product pricing actions in its core segments.Lamb Weston’s sturdy balance sheet and capacity to generate cash keep it well-placed to boost production capacity and fuel long-term growth. In July 2021, the company announced the expansion plan of french fry processing capacity at its existing American Falls, ID-based facility, with an envisioned capacity to manufacture more than 350 million pounds of frozen french fries and other potato products annually.The company earlier highlighted that the construction would be finished by the middle of 2023. In March 2021, the company unveiled plans to build a french fry processing facility in Ulanqab, Inner Mongolia, China. The construction of the facility was anticipated to be concluded in the first half of fiscal 2024.Lamb Weston’s efforts to boost offerings and expand capacity enable it to effectively meet rising demand conditions for snacks and fries. Apart from this, the company is continuing with investments to boost supply-chain, commercial and information technology operations. In the fiscal second quarter, capital expenditure (including IT expenditure) amounted to $148.1 million. For fiscal 2022, the company expects $450 million cash to be used for capital expenditure (excluding buyouts).Cost HurdlesLamb Weston has been seeing escalated costs for a while. In second-quarter fiscal 2022, gross profit declined $18 million to $205.5 million, led by increased manufacturing and distribution costs on a per-pound basis. Increased costs per pound reflect double-digit cost inflation from key inputs, mainly edible oils, ingredients like grains and starches, transportation and packaging. Adverse impacts of labor shortages on production run-rates and reduced raw potato utilization rates also led to increased costs per pound.Net income and adjusted EBITDA (including unconsolidated joint ventures) are likely to be under pressure for the rest of fiscal 2022, as it continues to navigate through major inflation for key production inputs, transportation and packaging compared with the fiscal 2021 levels.Also, industry-wide operational challenges like labor shortages, upstream and downstream supply-chain disruptions might be concerning. The company also expects raw potato costs on a per-pound basis to increase through the year. Apart from this, growth in sales volumes might be hampered by the disruptions in production and logistics networks along with the impacts of COVID-19 variants on restaurant traffic and consumer demand.The aforementioned upsides are likely to help the Zacks Rank #3 (Hold) company stay afloat amid such hurdles. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Hot Consumer Staples BetsSome better-ranked stocks are Flower Foods FLO, United Natural Foods UNFI and Sanderson Farms, Inc. SAFM.Flower Foods, the producer of packaged bakery foods in the United States, currently sports a Zacks Rank #1. Shares of FLO have gained 10.9% in the past three months.The Zacks Consensus Estimate for Flower Foods’ 2022 sales suggests growth of 1.9% from the year-ago reported figure. FLO has a trailing four-quarter earnings surprise of 15.4%, on average.Sanderson Farms, the producer of fresh, frozen and minimally prepared chicken, currently sports a Zacks Rank #1. Shares of SAFM have risen 0.7% in the past three months.The Zacks Consensus Estimate for Sanderson Farms’ current financial year’s earnings per share (EPS) suggests significant growth from the year-ago reported figure. SAFM has a trailing four-quarter earnings surprise of 496.3%, on average.United Natural Foods, the leading distributor of natural, organic and specialty food and non-food products in the United States and Canada, carries a Zacks Rank #2 (Buy) at present. Shares of UNFI have moved down 1.4% in the past three months.The Zacks Consensus Estimate for United Natural Foods’ current financial year’s EPS suggests growth of 7.7% from the year-ago reported number. UNFI has a trailing four-quarter earnings surprise of 35.4%, on average. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Flowers Foods, Inc. (FLO): Free Stock Analysis Report United Natural Foods, Inc. (UNFI): Free Stock Analysis Report Sanderson Farms, Inc. (SAFM): Free Stock Analysis Report Lamb Weston (LW): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksJan 13th, 2022

How DreaMed’s Recent AI Innovation Is Revolutionising Diabetes Care

Top US children’s hospital is utilising DreaMed’s FDA-approved AI platform to provide millions with access to sequestered diabetes staff and endocrinologists An Israeli biotech startup, DreaMed, has developed an AI system that has the potential to completely renovate the way in which the healthcare industry approaches the treatment of diabetes. Under the current system, the […] Top US children’s hospital is utilising DreaMed’s FDA-approved AI platform to provide millions with access to sequestered diabetes staff and endocrinologists An Israeli biotech startup, DreaMed, has developed an AI system that has the potential to completely renovate the way in which the healthcare industry approaches the treatment of diabetes. Under the current system, the ratio of endocrinologists to cases is 1:41,000; as a consequence, over half of recorded diabetic cases result in medical mismanagement. Since over 460 million people are affected by diabetes globally, according to the WHO, DreaMed’s solution presents significant benefits. Successful implementation would reduce administration costs associated with fewer clinical visits, an effort that could save the US billions of dollars per year. With the development of its artificial intelligence-utilising system, Advisor Pro, DreaMed has situated itself at the precipice of the healthcare industry’s revolution in attempting to rectify the holistic and systemic mismanagement of diabetes cases that is occuring on a massive scale in the US’s healthcare system. Advisor Pro’s focus has been guided towards helping those seek treatment for the ailment of Type 1 diabetes since 2018, when it was initially approved by the US Food and Drug Administration. Its expertise is based on over a decade of clinical research and data from hundreds of people suffering from diabetes, setting it apart from any other vendor in the diabetic digital healthcare industry. A New, Groundbreaking Approach Since its first authorisation by the FDA, Advisor Pro’s recent progressions have driven it to new heights; namely, the unique medical equipment’s capabilities were extended to include individuals suffering from type 2 diabetes now as well due to discoveries by the scientific team of DreaMed. All patients are different, so they are granted an exclusive profile in order to monitor their unique diabetic status and insulin levels. In order to manage the treatment of such highly variable conditions optimally, an acutely tailored and customised treatment plan, along with extensive supervision would normally be required. However, as a result of DreaMed’s innovative product, each patient’s data from their CGM, SMBG and insulin pump is stored in their platform; this data is then used by an AI system designed by leading clinicians and endocrinologists to generate a treatment plan that is just as helpful to the patient, yet infinitely simpler in its process. A simpler, more efficient process requires less clinical visits, which reduces the administrative costs associated with treatment (equating to billions of dollars a year alone). Therefore, DreaMed presents an opportunity to such healthcare providers, as well as the industry as a whole, the chance at a substantial financial advantage. Why This Is Special The benefits of DreaMed’s product are not limited to the financial realm, and actually include tangible benefits for the receivers of treatment as well. Moreover, leading pediatricians have gone on record to state that the Advisor Pro has been improving patient quality of life since the clinical trials phase. On top of this, the treatment will be significantly less financially intrusive for the patient as a result of the reduced clinical appointments that will be required when the most efficient treatment plan is assigned from the start through the use of DreaMed’s MD Logic-based algorithm. The plan that it develops eloquently and seamlessly elucidates the monitoring process of treatment, from the perspective of both the patient and the healthcare provider. This breakthrough is so incredibly important because its applicability is so widespread. Furthermore, it will connect millions of patients suffering from diabetes with lifesaving treatment that they might not otherwise have been under the old system. Given the scale of diabetes’s impact (around 460 million currently, and nearly 700 million by 2045), this generational leap has been innovated at the perfect time to counter one of the World Health Organisation’s most widespread, chronic diseases from around the world. Closing Remarks On balance, the breakthroughs that DreaMed have made with its innovative Advisor Pro system undoubtedly present a meaningful solution to one of the most inefficient treatments of a massively widespread disease. In doing so, it provides a better quality of life for the patients, alongside financial benefits for both patients and providers as a result of a more efficient treatment plan and the reduced number of clinical appointments this entails. It is no surprise that this company has developed such significant professional validation for the use of its AI algorithms to treat a plethora of chronic diseases. Clinical centres with a global reputation are so positively outspoken about this product, including Medtronic Diabetes, Yale-New Haven, Glooko and DexCom. With all that being said, there are still more improvements to be made. Whilst FDA approval and the consequential partnerships this have caused enable DreaMed to potentially benefit thousands of lives, their system is still faced with a myriad of obstacles if it hopes to offer advice that is comparable to the comprehensiveness and all overarching opinions of a human endocrinologist. Updated on Oct 29, 2021, 7:48 am (function() { var sc = document.createElement("script"); sc.type = "text/javascript"; sc.async = true;sc.src = "//mixi.media/data/js/95481.js"; sc.charset = "utf-8";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(sc, s); }()); window._F20 = window._F20 || []; _F20.push({container: 'F20WidgetContainer', placement: '', count: 3}); _F20.push({finish: true});.....»»

Category: blogSource: valuewalkOct 29th, 2021

Business trends for 2023 include AI, blockchain, secondhand shopping, and health

Founders Insider surveyed said more companies will adopt AI technology, wellness brands will rise, and e-commerce will continue to boom. Cynthia Plotch, Ronan Levy, and Ariela Safira.Stix, Field Trip, Real Insider asked 68 founders for their predictions of popular business trends and topics in 2023. Some bet on AI and blockchain tech, while others will look to the health and wellness spaces.  Here's what these founders predict will be the biggest trends in business this year.  This year, startups are poised to make major strides in healthcare, artificial intelligence, and cannabis. That's according to 68 founders Insider surveyed for their predictions of what's to come in 2023. Of course, the future is uncertain, but these entrepreneurs discussed themes like how companies can adopt AI and blockchain technology, consumer health, and brand transparency. Several founders are betting on healthcare and wellness, as they believe more people will take charge of their health and demand higher standards in the products and services they buy. "Over the last few years, we've seen a shift to consumers caring more than ever about their health, the transparency around the sourcing of ingredients, and the alignment around mission-driven brands," Katerina Schneider, the founder and CEO of the multivitamin-and-supplement startup Ritual, said.Meanwhile, other founders predict this will be the year for AI and blockchain to take off. Here are some of their predictions for 2023. Some responses have been edited and condensed for clarity.1. Artificial intelligence will reach widespread adoptionMatt Woodruff, the chief product officer and a cofounder of Constellation.ConstellationMatt Woodruff, the cofounder and chief product officer of the SaaS company Constellation"The industry that'll be poised to gain market value in 2023 will be the tech companies that are innovative in transformative technologies such as artificial intelligence. We already are seeing consumers dabble in the AI craze now, flooding Instagram with photos of them using AI-art applications. The businesses who embed the right technology like AI throughout their processes and in every area of operations are the ones who will stand out in 2023."2. Blockchain will make a comebackTim Dierckxsens, a cofounder of Venly.VenlyTim Dierckxsens, the cofounder of the Web3 company Venly"Blockchain and NFTs are the first to see the value of using the technology for their specific use cases. Whether it is a business case around fan engagement, loyalty program, in-game asset ownership, or royalty distribution, the technology is maturing and businesses are starting to see the benefits."3. 'Better-for-you' brands are here to stayKaterina Schneider, the founder and CEO of Ritual.RitualKaterina Schneider, the founder and CEO of the multivitamin-and-supplement startup Ritual"I believe 'cleaner' and 'better-for-you' brands are here to stay in 2023, whether it's in the food industry, the supplement industry, or home goods and even cookware. Additionally, it's no longer enough to be just clean, brands have to be clear with their standards around what is in their products."4. People will crave healthier snacksKatie Wilson, a cofounder and the CEO of BelliWelli.BelliWelliKatie Wilson, a cofounder and the CEO of the vegan-snack brand BelliWelli"Consumer trends have shifted to health and wellness; many consumers tend to care more and more about what foods they put in their bodies. I think the demand for better-for-you food and healthier versions of comfort food is going to uptick in 2023."8. Gen Z and millennials are fueling a new wave of wellness brandsGabriella Tegen, a cofounder and the CEO of Smartrr.SmartrrGabriella Tegen, a cofounder and the CEO of the e-commerce-subscription platform Smartrr"As a result of the pandemic, the wellness industry, more specifically within the e-commerce sector, has been exploding. The demand for wellness supplements, which aid diet and improve a person's health function, has skyrocketed post-Covid. Gen Z and millennials are especially embracing this trend. As a result, this group is fueling a new wave of lifestyle-product brands that are seeing a lot of success as online brands."5. Climate and greentech companies will gain market valueAlpay Koralturk, the founder and CEO of the furniture-resale platform Kaiyo.KaiyoAlpay Koralturk, the founder and CEO of the furniture-resale platform Kaiyo"Climate and greentech companies will gain market value in the coming year and beyond. There's a large amount of federal money that will be deployed. VC's are also getting more interested in the space."6. Lab-grown diamonds will gain popularityCarolina Cordón-Bouzan, a cofounder and the creative director of Montserrat New York.MontserratCarolina Cordón-Bouzan, a cofounder and creative director of the jewelry brand Montserrat New York"I believe 2023 will be a great year for the lab-grown diamond-jewelry industry, as consumers become more cost-conscious and begin to recognize the value in the fact that lab-grown diamonds are exactly the same as mined diamonds at a fraction of the cost.The diamond-jewelry industry has been stagnant for years and is ripe for change, and is thus coming at a time that converges with the consumer behaviors and expectations of millennials and Gen Z who are looking for more environmentally-friendly alternatives while upholding quality in their jewelry purchases that will last for years and become heritage pieces."7. E-commerce will continue to boomSivan Baram, a cofounder and the CEO of Radd.RaddSivan Baram, a cofounder and the CEO of the social-shopping platform Radd"E-commerce is one of the fastest growing industries and I am sure it will continue to boom. I personally feel that shopping online is making my life easier, enabling me to dedicate time to my family, friends, and outdoor activities I like."9. Subscription businesses will outperform customer-acquisition costsJonathan Zacharias, a cofounder and the president of GR0.GR0Jonathan Zacharias, a cofounder and the president of the marketing agency GR0"Subscription businesses. The cost per acquisition for marketing is skyrocketing. The only businesses that make sense now in e-commerce are ones where you can afford to pay a lot for a new customer because they continue to buy the products. One example is Tony Robbin's new subscription company LifeForce. This is an anti-aging company where they give you a blood test and do hormone balancing."10. People will take their health into their own handsCynthia Plotch, a cofounder and the CEO of Stix.StixCynthia Plotch, a cofounder and the CEO of the women's-health brand Stix"In 2023, I predict that consumer health will gain market value. With the looming recession, people are going to take more things into their own hands to avoid expensive doctor visits and save costs."11. Mental healthcare will begin to focus more on childrenAriela Safira, a founder and the CEO of Real.RealAriela Safira, the founder and CEO of the mental-wellness membership Real"In 2023, products and services that promote children's mental health are poised to gain value. While mental health for the adult population needs changing urgently, kids' mental health is plummeting at a rate we've never seen before. From the pandemic to social media, this generation of kids is facing anxiety, depression, and self-harm at rates we've never seen before." 12. Sexual health will take center stageStephanie Estey, left, and Daphne Chen, the cofounders and co-CEOs of TBD Health.TBD HealthDaphne Chen, a cofounder and co-CEO of the at-home STD/STI-screening-kit company TBD Health"2023 is going to be a big year for setting new expectations for what it means to be sexually healthy and happy, and we will see continued consumer investment in healthcare experiences that are sex-positive, accessible, and affordable.For example, the COVID-19 pandemic has taught us all that preventative measures and routine testing are important for keeping ourselves and others healthy from infection — a lesson we're seeing reiterated with the massive increase in sexually transmitted infections. As a result, there's been accelerated adoption of healthcare services like at-home testing that make it more convenient to get tested and treated."13. Healthcare innovation will reach rural locationsAshley Tyrner, the founder and CEO of FarmboxRx.FarmboxRxAshley Tyrner, the founder and CEO of the produce subscription service FarmboxRx"Healthcare, I believe, will gain a large momentum as we are really beginning to look at a whole-person model of care within a value-based care model. I also think rural-healthcare solutions will see a boom as we are beginning to wake up to the realities that rural America faces when trying to access healthcare."14. Expect to see more biotech products coming to marketShaun Veran, the founder and CEO of Ouragins.OuraginsShaun Veran, the founder and CEO of the medical-apparel brand Ouragins"The biotech industry saw massive levels of investment during the pandemic. These funds have been utilized to develop, test, and scale new innovations in the space to help mitigate, treat, and cure diseases. Expect to see many of these products coming to market in the coming year leading to gains in valuation."15. Menopausal healthcare will gain more attentionSuki Mulberg Altamirano, the founder of Lexington Public Relations.Lexington Public RelationsSuki Mulberg Altamirano, founder of Lexington Public Relations"Products targeted at supporting menopausal health have gained a lot of attention toward the end of the year and the first CEO Menopause Summit took place in NYC in October. Women are seeking targeted health-and-wellness products at all stages of life and this is poised to be a fast growth sector in the new year."16. Cannabis and psychedelics will make major stridesRonan Levy, a cofounder and the CEO of Field Trip Health.Field TripRonan Levy, a cofounder and the CEO of the psychedelic-therapy company Field Trip Health"Psychedelics will become the dominant form of mental-health treatment in the coming years. Like blockchain, however, psychedelic investments have been hit hard in 2022 but are poised to come back in 2023.As the world continues to open up to cannabis, the cannabis industry will continue to grow into a massive sector. Delays in US legalization efforts have slowed the growth in this industry but as countries like Mexico, Thailand, and Germany move to liberalize access, cannabis companies will continue to grow."17. The secondhand market will gain momentumAbigail Price, the founder and CEO of Abbode.AbbodeAbigail Price, the founder and CEO of the vintage-home-decor shop Abbode"I think the new-fashion industry is struggling, but the secondhand market is continuing to boom. Consumers are getting sick of fast fashion, looking like everyone else, and buying secondhand items has become completely normalized. Craftsmanship and quality is constantly declining, so to get items at an affordable price that are also made well, everyone is looking to shop vintage." If you're a founder with a prediction to add to this list, please reach out to this reporter at jortakales@insider.com. Read the original article on Business Insider.....»»

Category: personnelSource: nytJan 6th, 2023

Health tech and biotech startups landed $88 billion in funding in 2022. See 16 of the hottest pitch decks founders used to raise millions from investors.

From digital health to drug discovery, these are the 16 pitch decks used by healthtech and biotech founders to raise billions in VC funding in 2022. Caroline Noublanche, founder and CEO of Apricity.Apricity. Investors poured $13.5 billion into European health startups in 2022 and $88 billion globally, per Dealroom. Startups in digital health, pharma, and healthcare-staffing secured big rounds. Here are 16 pitch decks that health and biotech founders used. Startups operating in health tech and biotech enjoyed a bull run in the wake of the pandemic, with 2021 proving a record-breaking year for external investment.The run was short-lived, however, with the Russia-Ukraine war and the broader rout on tech stocks lowering the amount of capital available to founders. Still, a number of early- and mid-stage startups — many of which began collaborating with public health providers such as the National Health Service (NHS) — raised notable rounds. Investors focused particularly on digital health, remote monitoring, and drug discovery startups.Startups that catered to niche demographics, or pioneered novel technology, also saw investor traction from investment firms, angel investors, and government bodies alike.Vira Health, a startup offering personalized menopause care, bagged $12 million from Octopus Ventures, while James Corden backed wellness startup Hintsa in its $5 million round. In Germany, medical imaging startup NVision secured a $17 million government grant alongside a partnership with Siemens. Here are 16 of the pitch decks used by health and biotech founders to attract investor funds.Health techRachel Sanders, CEO of RootineRootineHealth tech is an umbrella term encompassing everything from digital health and therapeutics, to healthcare automation and staffing platforms.The industry saw tremendous growth in 2020 and 2021, as healthcare providers reeled from the pressures of the pandemic, staff shortages, and mounting backlogs.Against a backdrop of cooling investor interest globally, these 11 startups raked in millions in 2022. Vira Health wants to make personalized menopause care the norm. Check out the 8-slide pitch deck it used to raise $12 million in fresh funds.Check out the 10-slide pitch deck Ryse Health, a startup modernizing care for type 2 diabetes patients, used to land $3.4 millionCheck out the 12-slide pitch deck PillSorted, an automated prescription delivery startup, used to raise $6 million in a round backed by the DoorDash founderFlorence is bringing the gig economy to nurses and social care workers. Check out the 20-slide pitch deck it used to raise $35 million.This Cambridge University spinout helps diagnose mental health conditions. Check out the 9-slide pitch deck Psyomics used to raise $2.9 million.This startup wants to transform how alcohol addiction is treated. Check out the 24-slide pitch deck Ria Health used to raise $18 million.Wellness coaching startup Hintsa just raised $5.23 million in a round backed by James Corden. Check out the 45-slide pitch deck it used to raise the funds.This startup helps healthcare providers offer better virtual care. Check out the 18-slide pitch deck Healthie used to raise $16 million.This startup that aims to tackle healthcare staff shortages just raised $24 million. Check out the 15-slide pitch deck Patchwork Health used to raise the funds.Apricity wants to help patients maximize their chances of getting pregnant. Check out the 19-slide pitch deck it used to raise $17 million.This startup offers personalized nutrition treatments to athletes and consumers alike. Check out the 29-slide pitch deck Rootine used to raise $10 million.BiotechStef van Grieken, cofounder of Cradle.CradleIn the race to find a viable COVID-19 vaccine, biotechnology startups operating in medical research and drug discovery took center-stage during the pandemic, bringing in over $58 billion globally in funding in 2021.Here are five pitch decks biotech founders used to secure funding. This biotech startup is developing a vaccine for honeybees. Check out the 16-slide pitch deck Dalan Animal Health used to raise $3.5 million.These 3 founders are using AI to analyze patients' biological profiles and recommend drugs. Here's the 15-slide pitch deck they used to raise $5 million backed by Microsoft.Medical-imaging startup NVision says its quantum tech is a big step forward for catching cancerous tumors. Check out the 18-slide deck used to raise a $17 million grant.This startup is developing a medical food that treats migraines. Check out the 17-slide deck KetoSwiss used to raise $4 million in seed funding.This former Googler's stealth startup helps scientists design proteins using AI. Check out the 16-slide deck Cradle used to raise $5.4 million in seed funding.Read the original article on Business Insider.....»»

Category: dealsSource: nytJan 3rd, 2023

Industry City to Be Home of BK-XL, Largest Startup Accelerator for BIPOC Founders, Launched by BK Nets Owner

Industry City, the 16-building, 35-acre innovation campus on the Brooklyn waterfront, has been announced as the future home of BK-XL, the largest startup accelerator for BIPOC founders by total potential investment size. Applications for BK-XL launched this week and are open through January 20, 2023, offering each recipient up to $500,000... The post Industry City to Be Home of BK-XL, Largest Startup Accelerator for BIPOC Founders, Launched by BK Nets Owner appeared first on Real Estate Weekly. Industry City, the 16-building, 35-acre innovation campus on the Brooklyn waterfront, has been announced as the future home of BK-XL, the largest startup accelerator for BIPOC founders by total potential investment size. Applications for BK-XL launched this week and are open through January 20, 2023, offering each recipient up to $500,000 in investment funds, space at Camp David, Industry City’s creative co-working space, and ongoing investor support and mentorship opportunities. Launched by Clara Wu Tsai, founder of the Social Justice Fund and owner of the Brooklyn Nets, New York Liberty, and Barclays Center, in partnership with Visible Hands, BK-XL will select 12 BIPOC-founded startups for its inaugural 2023 cohort. Recipients will receive up to $500,000, including an initial investment of $125,000 (in return for seven percent equity) and an additional investment of $375,000 via an uncapped SAFE (upon meeting specific growth benchmarks and maintaining operations in Brooklyn for at least one year). In operating BK-XL, the Social Justice Fund is partnering with Visible Hands, a trusted investment platform and accelerator for early-stage, overlooked founders. “Our intention is to identify the most innovative BIPOC founders and provide them with the funding and network support they need to build scalable and sustainable businesses,” said Clara Wu Tsai. “With BK-XL, we’re bringing the best and brightest BIPOC talent to Brooklyn and giving them the same level of investment and access to resources that others have enjoyed for decades.” Selected founders will participate in a ten-week immersion program, located at Industry City, during which they will receive mentorship and support from investors and operators at Blue Pool Capital, Visible Hands, BSE Global, the Brooklyn Nets, Barclays Center, and other partnering organizations. BK-XL and its network of partners will continue to support the selected companies after the completion of the accelerator program. “BK-XL is a perfect complement to the unique business ecosystem that exists at Industry City, joining 550 companies who work across industries,” said Glen Siegel, Managing Partner at Industry City (Belvedere Capital.) “We are delighted to expand our relationship with the Tsai family and the Brooklyn Nets.” Among the industry-disrupting businesses headquartered at Industry City is Aanika Biosciences, a biotech company on a mission to make the global food chain more safe and transparent; Melonfrost, a startup whose proprietary software combines machine learning and evolutionary biology to steer the evolution of organisms in real-time; and Fundraise Up, an AI-powered fundraising platform for nonprofits. Support for BIPOC-owned and -founded startups is critical, particularly in New York City, where, while the Black community makes up 22 percent of the city’s population, only 3.5 percent of NYC businesses are owned by Black entrepreneurs. According to Crunchbase, only 2.4 percent of all U.S. venture capital raised from 2015 to 2020 was allocated to companies with Black or Latinx founders. Meanwhile, the BIPOC talent pool within the tech sector is stronger in New York City than in other major markets, with Black and Hispanic workers making up 21 percent of its tech sector, compared to less than 10 percent in the San Francisco Bay area and in Boston. Applications for BK-XL are currently open with a close date of January 20, 2023. Selected companies will be notified by early March 2023, and the program is expected to begin in mid-April of 2023 and run until late June 2023. Founders of early-stage startups whose racial identities are under-represented, e.g., Black, Indigenous, or people of color (“BIPOC”), are eligible to apply. Applications from founders throughout all sectors are welcome, and applications from startups in sports/media, e-commerce, and fintech/web3 are encouraged. More information on the timeline and application process is available at BK-XL.com. The post Industry City to Be Home of BK-XL, Largest Startup Accelerator for BIPOC Founders, Launched by BK Nets Owner appeared first on Real Estate Weekly......»»

Category: realestateSource: realestateweeklyDec 7th, 2022

Futures Slide As Recession Fears Trump China Reopening

Futures Slide As Recession Fears Trump China Reopening US futures slumped for a fifth day as investors faded the latest China reopening news - which saw Beijing move definitively away from its long-held Covid Zero approach as it eased a range of restrictions - as the latest dismal Chinese trade data reaffirmed the risk of a global recession. Contracts on S&P 500 futures dumped 0.7% at 7:20 a.m. ET with selling picking up US traders came to their desks after trading unchanged for much of the overnight session, and after the underlying gauge fell Tuesday for a fourth straight day and closed at the lowest level in nearly a month. Nasdaq 100 futures were down 0.8%  US futures are weaker as part of a global risk-off tone; MegaCap tech is again driving weakness, with Apple sliding after a key supplier warned of weaker demand. US/Global recession concerns seemingly outweighing the positivity surrounding China’s growth prospects. US lawmakers proposing an easing of restrictions on Chinese-made chips. SPX sits at its 100dma after falling below its 200dma this week; do we see follow-on selling from CTAs? Oil weakness continues and WTI sits ~11% above its 52-week low. EIA increased its 2023 oil production forecast. In politics, Warnock defeated Walker, giving Dems a 51-49 Senate majority; no immediate market impact. Today’s macro data include mortgage applications (-1.9%, vs -0.8% last week), labor costs, nonfarm productivity, and consumer credit. In premarket trading, Apple dropped more than 1% as mobile industry bellwether Murata Manufacturing expects the firm to reduce iPhone 14 production plans further in the coming months because of weak demand with the company’s president saying that handset stock in stores suggests slow demand. Last month, Bloomberg reported that Apple expects to make at least 3 million fewer iPhone 14 handsets than originally expected. Here are the most notable premarket movers: Chinese stocks listed in the US fall in Wednesday’s premarket trading, as Beijing’s new measures to ease Covid restrictions presented an opportunity for traders to lock in profit after recent rallies. Alibaba (BABA US) -4.5%, Baidu (BIDU US) -3.4%, Pinduoduo (PDD US) -4.1%, Bilibili (BILI US) -5.2%, Nio (NIO US) -4.5%, XPeng (XPEV US) -5.9% MongoDB (MDB US) shares rallied 28% after the database software company reported third-quarter results that beat expectations and gave a fourth-quarter revenue forecast that analysts see as strong. Toll Brothers (TOL US) shares advance 1.2% after the luxury home builder’s adjusted home sales gross margin forecast for 2023 beat estimates, with Citi positive on the better visibility for next year amid a difficult housing market. Pinterest gains 1.8% after the social media company added a board seat for Elliott Investment Management as part of a cooperation agreement with the activist investor. Carvana shares rise as much as 3% before paring gains after Bloomberg reported that some of its largest creditors, including Apollo and Pimco, signed a cooperation agreement to prevent the creditor fights that have complicated other debt restructurings in recent years. Summit Therapeutics fell, reversing earlier gains in premarket trading. On Tuesday, the shares soared 194% following the announcement of a partnership deal with Akeso to in-license ivonescimab, its breakthrough bispecific antibody. Watch Illumina stock as it was initiated at RBC with a recommendation of outperform, with the brokerage citing the biotech company’s competitive advantage in the next generation sequencing market. Keep an eye on Autoliv stock after UBS downgraded it to neutral, saying that the shares now offer limited valuation upside, while the airbag maker’s medium-term profitability targets look ambitious. Watch shares in US oil explorers as Citi says it does not foresee a further re-rating for the sector in 2023 for a number of reasons, in a note double-downgrading its rating on Comstock to sell, cutting Coterra to sell and moving EQT and Southwestern Energy down to neutral. Traders are also monitoring developments in China. The Asian country eased a range of Covid restrictions Wednesday in a sharp change in national strategy to quell public discontent and fire up the economy again. Meanwhile, statistics showed that the nation’s exports and imports both contracted at steeper paces in November - and absent the covid crash in early 2020, the fastest pace since 2016 - as external demand weakened and a worsening Covid outbreak disrupted production and cut demand at home. US stocks have started unwinding recent gains after strong jobs data and an unexpected increase in a US service-sector gauge stoked concerns the Fed will remain aggressive in tightening policy. Investors are growing wary that higher-for-longer interest rates will curb growth and corporate earnings. “We’re still in for a fairly rough period,” Shane Oliver, head of investment strategy and economics at AMP Services Ltd told Bloomberg Television. “Monetary conditions have gone from super easy to super tight. That is going to have economic consequences, with a sharp slowing in growth and possibly a mild recession.” Oliver expects a year-end rally after next week’s Fed meeting is out of the way before stocks test new lows in the first half of 2023. A recovery is likely to take place in the second half as monetary policy starts to ease again, he said, echoing Michael Wilson almost verbatim. The S&P 500’s worst selloff in a month was sharp enough to reverse the rally that followed Fed Chair Jerome Powell’s comments on a possible downshift in the pace of tightening, leaving the benchmark where it was a week ago just before he spoke. “Recent economic data has highlighted the uncertainty over the economic outlook and the Fed’s response,” Mark Haefele, UBS Global Wealth Management’s chief investment officer wrote in a Wednesday note. “We expect further volatility and maintain our defensive exposure.” European stocks fell for a fourth consecutive day, the longest run in almost two months. Energy, miners and telecoms are the worst-performing sectors, dragging most European stocks lower. Euro Stoxx 50 falls 0.4%. FTSE MIB outperforms peers. Here are the biggest European movers: Russia is considering either imposing a fixed price for its oil or stipulating maximum discounts to international benchmarks at which it can be sold, according to two officials familiar with the plan, as a response to a cap that the G-7 nations set out last week. France’s Engie (ENGI FP +0.1%) agreed to a 15-year contract to buy liquefied natural gas from Sempra Infrastructure as companies increasingly look for long-term supply from the US to avoid shortages. Salzgitter and Engie have concluded a power purchase agreement with volumes of about 250 GWh of electricity per year. ERG gains in Milan to be among the best performers on the FTSE MIB index, which it joined on Nov. 29. Intesa Sanpaolo notes positive stance on the stock is backed by “solid” fundamentals and a dividend yield above the sector average. French renewable- energy company Voltalia drops after an offering of 35.8m shares priced at €13.70 apiece, representing a discount of about ~26% to Monday’s close. Oil and gas firm Mol has restarted its Danube refinery in Hungary and is gradually ramping up capacity, though won’t be able to meet market demand as the supply situation has become “critical,” Gyorgy Bacsa, managing director of Mol Hungary says in emailed statement Credit Agricole SA said it would stop new financing for oil extraction immediately, as part of bank’s efforts to cut the carbon emissions caused by its lending to fossil-fuel companies by a third by the end of the decade. European equities have been outperforming their US counterparts since the lows of late September. As Bloomberg notes, the Stoxx Europe 600 moved beyond its 2022 downtrend and crossed the much-watched 200-day moving average a month ago, while its US counterpart is struggling to overcome that resistance level. The difference in technical setups might further widen the performance gap as it suggests a bearish view for the US and a bullish one for Europe. Earlier in the session, Asian stocks widened losses in the late afternoon as renewed concerns about China’s growth were revived by weak trade data, offsetting optimism as the nation moves away from its Covid-Zero policy.     The MSCI Asia Pacific Index slumped as much as 1.4% on Wednesday, its biggest drop in more than a week, led lower by consumer discretionary and information technology shares.  Benchmarks in Hong Kong plunged more than 3% in volatile trading as a selloff deepened following reports that mainland authorities are set to allow home quarantine and relax testing requirements. Weak trade data underscoring sluggish demand at home and abroad also hurt sentiment.  The market has already priced in the easing of Covid policy announced today, “so investors are selling on news,” said Banny Lam, head of research at CEB International.  The Philippine stock benchmark was among notable losers in the region, dropping 2.2% amid profit taking. Japanese stocks also declined, following US shares lower as downbeat warnings from bank chiefs deepened concerns over the global economy.  The Topix fell 0.1% to close at 1,948.31, while the Nikkei declined 0.7% to 27,686.40. Tokyo Electron Ltd. contributed the most to the Topix decline, decreasing 3.8%. Out of 2,164 stocks in the index, 1,202 rose and 816 fell, while 146 were unchanged. “With the comments from U.S. banks, there is increasing negative sentiment toward the global economy, and market participants are watching the shift of economic trends closely,” said Hirokazu Kabeya, chief global strategist at Daiwa Securities. Shares in Australia, Taiwan, Singapore and Indonesia also declined.  Asian stocks have been relatively shielded from recession woes that hurt US stocks this week as investors expected China’s reopening moves could bolster its recovery. Wednesday’s selloff highlighted how volatile the path for recovery could be.   The key Asian stock benchmark has risen more than 15% from its October low amid expectations for China’s full reopening and the Fed’s pivot from its aggressive tightening. The gauge’s rally has paused in recent days, stopping short of entering a technical bull market. India’s benchmark stock gauge declined after the central bank raised borrowing costs in line with expectations but surprised investors with a trimmed outlook for growth. The S&P BSE Sensex fell 0.3% to 62,410.68 in Mumbai, its lowest level since Nov. 25. The NSE Nifty 50 Index dropped 0.4%. Both initially rose after the Reserve Bank of India raised its key rate by 35 basis points to 6.25%. Reliance Industries and mortgage lender HDFC dragged the Sensex the most, as 22 out of its 30 stocks traded lower while the rest advanced. All but four of the BSE’s 19 sector sub-indexes declined, led by utilities.  “For stocks, it’s important to note that the RBI continues to take out liquidity,” said Amit Kumar Gupta, a chief investment officer at New Delhi-based Fintrekk Capital. Stocks will face pressure on the RBI’s comments about consumption and commodity prices, he added.  India is Asia’s best-performing stock market so far this year. Foreign investors have resumed buying on expectations that corporate earnings will improve despite inflationary pressures. In the five months through November, they have bought more than $11 billion in local shares, lifting benchmarks to a record. Some investors are concerned that economic growth is peaking. The “growth narrative looks rather weak,” Kotak Institutional Equities analysts led by Sanjeev Prasad wrote earlier this month In FX, the Bloomberg Dollar Spot Index steadied after earlier rising to a one-week high as the greenback traded mixed against its Group- of-10 peers. JPY underperforms G-10 FX, trading around 137.46/USD. The term structures in the major currencies retained inversion mode as next week’s US CPI print and meetings by the Fed, the BOE, the SNB and the ECB are in focus. The euro snapped a two-day drop against the dollar after recovering in the European session. The common currency neared $1.05 after earlier touching a low of $1.0443. Bunds and Italian bonds twist-steepened as yields inched lower through the 10-year tenor while rising further out on the curve. The pound inched up against the dollar to trade at around $1.2150. Gilt yields crept higher. Concern over a protracted downturn in the housing market persisted after data showed that UK house prices fell at the sharpest pace in 14 years in November. The Norwegian krone and the Canadian dollar were among the worst G-10 performers amid a decline in oil prices. The yen also fell as a Bank of Japan board member said a wage hike alone may not lead to an immediate change in policy. The yield curve twist-flattened. Recession fears were palpable in the bond market, where demand for longer-dated bonds drove a yield inversion to a four-decade extreme, sending 10-year rates below those on 2-year notes by the most since the early 1980s. The Federal Reserve rate decision and inflation data due next week loom as pressure points for a market governed by central banks. Bunds, USTs and gilts 10-year yields fairly muted with less than a basis point move within Tuesday’s range. The US Treasury curve bull steepened slightly. The two-year yield fell 2bps to 4.35% while the 10-year yield shed one 1bp to 3.52%. Gilts lag with the UK curve bear-steepening while Treasuries 5s30s spread extends flattening, dropping as low as -22.7bp, tightest since start of November. The UK 10-year cheaper by 1.6bp; 2s10s steeper by ~2.5bp on the day with front- end yields richer by 1bp on outright basis while 5s30s spread is flatter by ~1.5bp In commodities, oil fluctuated after touching the lowest level since last December on Tuesday as investors pared back crude positions amid a broader market sell-off. The decline for West Texas Intermediate, which settled near $74 on Tuesday, erased all of this year’s gains as sentiment remaining fragile on signs that tighter interest rates could be needed for longer. WTI rebounded back into the green, trading at $74.37 last after earlier dropping as low as $72.75. A Russian price cap coalition official said nearly all 20 tankers waiting to cross Turkey's straits are loaded with Kazakh oil and not subject to the G7's Russian oil price cap, while the delays in tanker traffic from Russia's Black Sea ports to the Mediterranean stem from the Turkish insurance rule and not the price cap, according to Reuters.  Chinese nickel buyers are seeking to use Shanghai Future Exchange contracts not London Metal Exchange for 2023 pricing, according to Reuters sources; participants write this is due to the decline in liquidity and low stocks which has resulted in persistently high prices within London this year, which have not reflected market fundamentals. Spot gold is contained around USD 1775/oz, while base metals are mixed but with an underlying downward bias. Looking to the day ahead, from central banks we’ll get the Bank of Canada’s latest policy decision, along with remarks from the ECB’s Lane and Panetta. Otherwise, data releases include German industrial production and Italian retail sales for October. Market Snapshot S&P 500 futures down 0.2% to 3,937.00 STOXX Europe 600 down 0.5% to 436.56 MXAP down 1.3% to 155.60 MXAPJ down 1.5% to 506.31 Nikkei down 0.7% to 27,686.40 Topix little changed at 1,948.31 Hang Seng Index down 3.2% to 18,814.82 Shanghai Composite down 0.4% to 3,199.62 Sensex down 0.1% to 62,535.48 Australia S&P/ASX 200 down 0.8% to 7,229.39 Kospi down 0.4% to 2,382.81 German 10Y yield down 0.7% to 1.79% Euro up 0.1% to $1.0481 Brent Futures down 1.7% to $78.02/bbl Gold spot up 0.1% to $1,772.93 U.S. Dollar Index little changed at 105.56 Top overnight news from Bloomberg Senator Raphael Warnock defeated Republican challenger Herschel Walker in their hotly contested runoff for Georgia’s US Senate seat, giving Democrats a 51-49 edge in the upper chamber Mexico’s central bank may start to slow the pace of interest-rate increases, Reuters reported A sense of calm that has narrowed the gap between German and Italian debt yields will embolden policymakers next week as they announce principles for so-called quantitative tightening. But whatever they devise under such placid conditions must accommodate the danger of renewed volatility Foreign investors are positioning for Japan’s sovereign yields to rise as quickening inflation increases the pressure on the BOJ to alter its accommodative stance. Overseas funds are sticking to their guns even as central bank chief Haruhiko Kuroda has vowed repeatedly to keep easing to spur price gains China moved definitively away from its long-held Covid Zero approach Wednesday, easing a range of restrictions that it has persisted with long after the rest of the world moved on to living with the virus Senior Chinese officials are debating an economic growth target for next year of around 5%, according to people familiar with the discussion, as Beijing shifts gears toward bolstering the recovery The EU will proceed with two cases against China at the World Trade Organization on Wednesday after talks to resolve the issues with its largest trading partner failed to yield results A More detailed look at global markets courtesy of Newsquawk Asia-Pacific stocks were mostly subdued after the losses on Wall St where risk sentiment was dampened by tech sector woes and recession concerns, while participants also digested weak trade data and an easing of restrictions in China. ASX 200 was pressured after Australian GDP data for Q3 missed forecasts and with the declines in the index led by tech and energy following similar weakness in US counterparts. Nikkei 225 was lacklustre but with downside limited by a lack of domestic catalysts and with BoJ’s Nakamura reiterating that the central bank must patiently maintain monetary easing. Hang Seng and Shanghai Comp were indecisive as the announcement of an easing of COVID restrictions was offset by the dismal trade data from China. Top Asian News China's Politburo said China will maintain its prudent monetary policy and that monetary policy should be targeted and forceful, while it urged coordinating COVID controls and economic development. China will also fine-tune COVID control measures and allow home quarantine, as well as ease testing, according to Xinhua. China's Health Commission said asymptomatic patients and cases with mild symptoms can undergo home quarantine, while it will accelerate vaccination of the elderly against new coronaviruses. Furthermore, China bans COVID movement restrictions in non-high-risk zones and scraps COVID test rules in most public venues nationwide, according to Reuters and Bloomberg. "Latest optimized measures against COVID do not represent a full re-opening or relaxation, but rather show that the country's anti-epidemic measures are becoming more scientific, more active and more accurately targeted", according to Global Time China is said to be considering a 5.0% GDP target for next year, according to Bloomberg. Shanghai Disneyland (DIS) to reopen on Thursday, December 8th. US Senators scaled back a proposal that placed new curbs on the use of Chinese-made chips by the US government and its contractors, according to a draft seen by Reuters. EU will proceed with two cases against China at the World Trade Organization on Wednesday after talks to resolve the issues with its largest trading partner failed to yield results, according to Bloomberg. RBI hiked the Repurchase Rate by 35bps to 6.25%, as expected, through 5-1 vote, while the Standing Deposit Facility was raised by 35bps to 6.00% and the Marginal Standing Facility was raised to 6.5%. RBI Governor Das said that inflation remains high and broad-based, as well as noted that the MPC will remain focused on the withdrawal of accommodation with 4 out of 6 in the MPC voting in favour of retaining the policy stance. Das added that further calibrated monetary policy is warranted to anchor inflation expectations and that they stand ready to act as necessary from time to time, while the focus on inflation continues and there will be no let-up in efforts to bring inflation to more manageable levels. European bourses are somewhat mixed after a predominantly soft cash open, Euro Stoxx 50 -0.5%; though, the breadth of the market remains narrow. Stateside, futures are in relative proximity to the unchanged mark and are yet to meaningfully deviate from overnight ranges, ES -0.2% at circa. 3935. In Europe, Health Care outperforms following Zantac updates for GSK (9.0%) & Sanofi (+5.5%) while Energy & Basic Resources lag given benchmark pricing. Key Apple (AAPL) supplier expects iPhone orders to drop on weak demand, via Bloomberg; "Mobile industry bellwether Murata Manufacturing Co. expects Apple Inc. to reduce iPhone 14 production plans further in the coming months because of weak demand, which would force the supplier to again cut its outlook for its handset-component business." Top European news UK PM Sunak is reportedly under pressure from Tory MPs to speed up anti-strike legislation, according to FT. ECB Consumer Expectations Survey (October): Consumer expectations for inflation 12 months ahead increased further, while expectations for inflation three years ahead remained unchanged. Europe Gas Rises as Cold Weather and China Shift Fuel Demand Prosus Valued at $31 Billion Excluding Tencent Stake Credit Agricole Stops New Oil Extraction Financing ECB Says 12-Month Consumer Inflation Expectations Rose Further Saxo Bank Shelves $2 Billion IPO After Dutch SPAC Deal Dropped UK Tones Down ‘Big Bang’ Finance Plan to Avoid Backlash FX USD is mixed vs G10 peers, though the DXY itself remains underpinned above 105.50. Overall, peers are narrowly mixed with EUR modestly outpacing and testing 1.05 while JPY lags as USD/JPY rebounds to near 138.00 CAD remains pressured given benchmark crude pricing with attention turning to the BoC with expectations split between 25bp and 50bp. NOK knocked on crude and domestic data, SEK gleaned limited traction from significantly better than forecast GDP. PBoC set USD/CNY mid-point at 6.9975 vs exp. 6.9941 (prev. 6.9746) Fixed income Overall, fundamentals little changed for the complex. Core benchmarks have drifted slightly down from intraday peaks. Bunds holding around 142.00 vs 142.65 peak, with USTs similarly at the bottom of a 114.03 to 114.13+ band yields marginally firmer, as such. Commodities Crude benchmarks are softer intraday given the cautious tone and resilient USD impacting the complex, despite further constructive China COVID updates. WTI has dipped under USD 73/bbl (vs USD 74.82/bbl high) while Brent Feb had lost the USD 78/bbl handle (vs USD 79.93/bbl high). US Energy Inventory Data (bbls): Crude -6.4mln (exp. -3.3mln), Cushing +0.0mln, Gasoline +5.9mln (exp. +2.7mln), Distillate +3.6mln (exp. +2.2mln) Price cap coalition official said nearly all 20 tankers waiting to cross Turkey's straits are loaded with Kazakh oil and not subject to the G7's Russian oil price cap, while the delays in tanker traffic from Russia's Black Sea ports to the Mediterranean stem from the Turkish insurance rule and not the price cap, according to Reuters. Hungarian government is to scrap its fuel price cap, according to PM Orban's chief of staff cited by Reuters. Chinese nickel buyers are seeking to use Shanghai Future Exchange contracts not London Metal Exchange for 2023 pricing, according to Reuters sources; participants write this is due to the decline in liquidity and low stocks which has resulted in persistently high prices within London this year, which have not reflected market fundamentals. Spot gold is contained around USD 1775/oz, while base metals are mixed but with an underlying downward bias. Crypto A new proposed amendment under National Defense Authorization Act (NDAA) could require the US Department of State to justify crypto rewards and disclose any crypto payouts within 15 days of making it, according to a document via CoinTelegraph. Geopolitics US Secretary of State Blinken said the US has neither encouraged nor enabled Ukraine to strike within Russia, according to Reuters. US Defense Secretary said the US military will increase the rotational presence of bomber task forces and other forces in Australia, according to Reuters. US State Department approved the sale of aircraft spare parts worth around USD 300mln to Taiwan and the sale of non-standard spare parts worth an estimated USD 98mln, according to the Pentagon, while Taiwan's Defence Ministry said the aircraft parts sale will help air force operations in the face of China's military activities, according to Reuters. US Event Calendar 07:00: Dec. MBA Mortgage Applications, prior -0.8% 08:30: 3Q Unit Labor Costs, est. 3.0%, prior 3.5%; Nonfarm Productivity, est. 0.6%, prior 0.3% 15:00: Oct. Consumer Credit, est. $28b, prior $25b DB's Jim Reid concludes the overnight wrap It's all crept up fast but today I'm taking an hour away from my desk to hobble to watch my 5-year-old twins in their nativity play. One of the twins has the lead role of Joseph and the other has just one line which is "I'm not a cow, I'm an Ox"! Ironically, I'm equally worried about both as although the latter has far less to do, he's shown little evidence at home that he understands his cue or how to say his line properly. With regard to the former, I will wince when he tells the innkeeper that "My wife is pregnant", and hope it's not a line he uses again for at least 20 years. Assuming we get over this, tomorrow it’s Maisie's turn for her play. As thoughts turn to Xmas and year-end, today we’re launching our final EMR survey of 2022 aimed at market participants (link here). This December edition is a special 2023 one with lots of easy-to-answer questions about the year ahead, with a few longer-term ones thrown in for consistency with prior surveys. It’ll close on Friday and will only take a few minutes to complete. Many of the questions look forward to the year ahead, including where you see the biggest market risks, the likelihood of stagflation, and where central banks will take their policy rates to. We have some seasonal ones as well, such as what’s your favourite Christmas song, and who you expect to win the football World Cup. All responses are very gratefully received, and everything is anonymous. Last year we had over 750 responses for our year-end survey, and it’s revealing what readers did and didn’t get right. A good call was that the two biggest risks were “Higher than expected inflation” and “an aggressive Fed tightening cycle”, both of which surprised well to the upside of consensus. But even then, very few saw quite how aggressive it would prove in the base case, with just 2% of respondents thinking US CPI would be above 7% by 2022 year-end, whilst the median estimate on Fed hikes was for 50bps this year. In reality, we’ll end up with 425bps if they go ahead with a 50bps move next week. Other interesting snippets were that just 19% thought the S&P 500 would post a negative return in 2022, and the average estimate for the 10yr Treasury yield by year-end was 1.9% with just 0.54% thinking they'd end this year above 3.5%. If you were any of those 4 people out of 750 please email me to tell me your predictions for the next 12 months. Before we get to 2023 we still have to survive 2022. The Santa Claus rally has struggled of late with last night continuing a streak of four successive losses for the S&P 500 (-1.44%) and seven down sessions out of eight. In fact, the latest moves for the S&P mean it’s now unwound the entirety of the rally following Fed Chair Powell’s speech last week, which makes sense on one level given he didn’t actually say anything particularly new. That said however, there hasn’t been a great deal of newsflow coming through, with markets still in something of a holding pattern ahead of next week’s bumper calendar of events, which includes the US CPI print as well as the Fed and ECB decisions. This gloomy outlook was evident from a number of indicators, not least the 2s10s Treasury curve which closed at its most inverted of this cycle yet, after falling -2.1bps on the day to -84.1bps, something we haven’t seen in over four decades. In the meantime, the prospect of weakening global demand led to a further slump in oil prices, with Brent Crude falling -4.03% on the day to $79.35/bbl. That’s its lowest closing level since January, and means that Brent Crude is now up by just +2.24% on a YTD basis, whilst WTI is actually now down -1.27%. One upside for policymakers is this is continuing to filter through to consumers, with average US gasoline prices now down to $3.38 per gallon, having been just above $5 back in mid-June. Elsewhere yesterday, the combination of moves made it a classic risk-off performance, with equities and HY credit struggling, whereas safe havens such as sovereign bonds and gold both advanced. For equities, the losses were led by the more cyclical sectors, with few strong performers as nearly 80% of the S&P 500 moved lower on the day. Tech stocks struggled in particular, with larger declines for the NASDAQ (-2.00%) and the FANG+ index (-2.33%). And over in Europe there were also broad-based declines, with losses for the STOXX 600 (-0.58%), the DAX (-0.72%) and the CAC 40 (-0.14%). In spite of the equity declines, the 60/40 portfolio didn’t have such a bad day yesterday thanks to a sovereign bond rally on both sides of the Atlantic. The moves were particularly pronounced in Europe, with yields on 10yr bunds (-8.4bps), OATs (-6.7bps) and BTPs (-10.0bps) all seeing sharp moves lower, including the lowest 10yr bund yield in a couple of months. That comes as market pricing continues to inch towards expecting a 50bps ECB hike next week, with the 53.6bps priced in for the December meeting being the lowest in nearly three months now. Meanwhile in the US, the moves were somewhat smaller and yields on the 10yr Treasury fell -4.2bps to 3.53%. Asian equity markets are mixed this morning. The Hang Seng (+1.38%) and CSI (+0.78%) jumped after China announced a significant loosening of Covid restrictions, saying it would allow home quarantine for some Covid patients and close contacts and would ditch Covid testing requirements in most public venues. This came hot on the heels of reports that officials are considering a growth target of around 5% for next year and offset disappointing early morning data showing that exports and imports in November fell to the lowest since early 2020. Exports dropped -8.7% y/y (v/s -3.9% expected) following a decline of -0.3% in the previous month while imports contracted -10.6% (v/s -7.1% expected) against October’s decline of -0.7%. Meanwhile, the Nikkei (-0.54%) and the KOSPI (-0.14%) are trading in negative territory. Outside of Asia, US stock futures are indicating a rebound with contracts tied to the S&P 500 and the NASDAQ 100 (+0.19%) edging higher. Elsewhere in the States, Democrat Raphael Warnock beat his Republican challenger in Georgia’s runoff to determine who they will send to the Senate. The outcome gives the Democrats a narrow 51-49 seat majority in the upper house. There wasn’t much in the way of data yesterday, although we did get the US trade balance for October, which showed a $78.2bn deficit (vs. $80.0bn expected). Elsewhere, the German construction PMI came in at a 20-month low of 41.5 in Germany, whilst the UK construction PMI just about remained in expansionary territory with a decline to 50.4 (vs. 52.0 expected). To the day ahead now, and from central banks we’ll get the Bank of Canada’s latest policy decision, along with remarks from the ECB’s Lane and Panetta. Otherwise, data releases include German industrial production and Italian retail sales for October. Tyler Durden Wed, 12/07/2022 - 08:06.....»»

Category: personnelSource: nytDec 7th, 2022

The 10 people transforming business across sectors, chosen by Insider readers — including execs from ABC News, Shopify, and Cart.com

Insider's 100 People Transforming Business highlights leaders who are driving innovation and change across 10 verticals. This year, we added a new category called Readers' Choice. Insider Graphics Insider's 100 People Transforming Business highlights 100 leaders across 10 industries who are driving unprecedented change and innovation. The Readers' Choice list includes leaders from such organizations as ABC News, Shopify, and Cart.com Click here to read the full profiles and see the complete list of Transformers. Insider has released its 2022 list of 100 people who are transforming business across different sectors. Keep reading to see the 10 leaders making waves who were nominated by our readers. Julia Cheek, CEO and Founder, Everly HealthLizzie Chen/InsiderIn June 2016, Cheek launched Everlywell with tests for women's fertility, metabolism, and food allergies. The company, based in Austin, Texas, now offers 30 tests for things like thyroid health, STDs, colon cancer, and more. Everly Health, Everlywell's parent company, said that last year it served more than 40 million people."Our goal is how can we help people get tests as cheaply and quickly as possible, driven by technology, so they can get the answers they need," she said. "And if they never have to leave our ecosystem to get those answers, even better."Read more.Lilac Bar David, CEO and Cofounder, LiliLilac Bar David, founder of LiliLiliAs the cofounder and CEO of Lili, a small-business-focused online bank, Lilac Bar David is at the forefront of an emerging group of fintech startups dedicated to working with the millions of entrepreneurs and freelancers in the US.A key selling point for Lili, David said, is that small-business customers can see higher refunds after using the app's tax tools — she estimated that the average tax refund for Lili customers totaled $4,500 this year while the IRS said that the nationwide average was roughly $3,000.  "When we are looking at the banking industry, it's one of the most exciting industries to be in today. This is one of the industries that has not been disrupted enough," David said.Read more.Kim Godwin, President, ABC NewsCourtesy of Kim GodwinAs the first Black female president of a US network news operation, Godwin boasts creating the most diverse team in ABC News history. Since landing the position in April 2021, increasing diversity, equity, and inclusion in the media industry has been a priority for her. This became evident during her first months on the job as she tapped several industry veterans from diverse backgrounds to expand her executive team and other top positions."Excuse-making is over. As executives, we must make a personal commitment to just do it," she told Insider when asked what her plan is to help increase accountability in the media industry.Read more.Rajatesh Gudibande, President and Cofounder, GraphWear Technologies Inc.Jeramie Campbell/InsiderGudibande is working to tackle chronic diseases and inequity in healthcare — all without a single needle prick.As the CEO and a cofounder of the biotech startup GraphWear Technologies, Gudibande is pioneering the first no-blood, no-needle glucose-monitoring test. It could be revolutionary for the 422 million people with diabetes around the world who must subject themselves to daily finger pricks to monitor their glucose levels.Read more.Nitin Gupta, CEO and Founder, Beans.aiPeter DaSilva/InsiderFor Gupta, the founder of Beans.ai, helping people navigate the last 100 yards of their journey is personal.While visiting from India, Gupta's mother had a medical emergency at his apartment. "The paramedics hit my property about 15 minutes before they found my apartment," he told Insider. His mom received treatment with just a minute to spare. "It was surprising that in a developed country like the US, the first responders don't have the data" to find where they need to go, he said. "They actually have this thick paper binder in every fire truck with less than a tenth of the relevant data that they flip through as they're going to an emergency."While the stakes are much lower, delivery professionals face the same challenges at sprawling apartment complexes and labyrinthine office buildings. By crowdsourcing information about the built environment, Beans.ai is helping people get where they need to go.Read more.Stacy Kauk, Head of Sustainability, ShopifyMichael Dupe/InsiderA decade into her career with the Canadian government working on environmental issues, Kauk realized something: The slow and consensus-driven nature of global climate diplomacy wouldn't solve the crisis fast enough."Governments try to minimize risk so they don't waste taxpayer dollars, so they can't make bets the same way the private sector can," Kauk told Insider. "Companies like Shopify have the ability to move quicker because we're more tolerant of failure."Read more.Ken Kim, CEO, Webtoon AmericasNolwen Cifuentes/InsiderSince taking on the role of CEO of Webtoon Americas in 2016, Kim has led the digital-comics company — which originated in South Korea — to new heights, with 15 million monthly users in the US and 89 million globally.His impact goes beyond the company's popularity. Kim has paved new ways for comics creators to express themselves, find audiences, and monetize their passions."It's not just professional creators," Kim told Insider. "They are from all over the world."Read more.Alex Lofton, President and Cofounder, LandedJamison Weeks/InsiderWhat if you could almost afford to buy a home but needed an extra $10,000 to do it?As home prices have skyrocketed nationwide up to $357,000, which Zillow says is a more than 14% climb over the past 12 months, many essential workers like teachers, restaurant employees, and firefighters found themselves in that situation.That's why Lofton, 38, started Landed, a company that wants to make the homebuying process easier to navigate.Read more.Ella Alkalay Schreiber, General Manager of Fintech, HopperHannah Latham/InsiderFor travelers who want to buy some peace of mind, Hopper's app can help book a flight or hotel as well as provide the ability to cancel for any reason or lock in a flight price. As the head of fintech, Schreiber leads the team of data scientists that makes those guarantees possible for customers — and profitable for Hopper.Over the past several years she's helped launch about a dozen add-on products, which have grown to account for 40% of all revenue at the company according to Hopper. Schreiber said that half of all bookings carry a fintech product and that customers who buy them are eight times as likely to buy one the next time they book with Hopper."Fintech basically led the entire recovery from the pandemic," Schreiber said.Read more.Omair Tariq, CEO and Cofounder, Cart.comAl Torres/InsiderWhile serving as a top exec at Home Depot, Tariq realized people used multiple e-commerce sites to shop, but retailers couldn't stitch all those interactions together and track sales.So in 2020, he founded Cart.com to provide that backbone, and today, the company's technology is used by more than 6,000 brands, including the fashion retailer Guess and the skiwear brand Halfdays, to handle e-commerce analytics, inventory management, online storefronts, and digital marketing."We want to be the commerce-enablement infrastructure for the largest brands in the world," he said.Read more.Read the original article on Business Insider.....»»

Category: topSource: businessinsiderNov 23rd, 2022

How Two Story Is Taking Over Workplace Performance Analytics

When you run a business, you want as many high performers as you can get. The problem is, absent performance analytics, it can be hard to determine the exact attributes that make some employees stand out. Sure, you can see that one person comes in early and stays late. And you know that another person […] When you run a business, you want as many high performers as you can get. The problem is, absent performance analytics, it can be hard to determine the exact attributes that make some employees stand out. Sure, you can see that one person comes in early and stays late. And you know that another person has fantastic sales conversions. Yet you can’t quite pinpoint all their contributions. And you know if you could, you’d be able to hire others like them, help your current employees reach their fullest potential, and get a competitive edge in your industry. if (typeof jQuery == 'undefined') { document.write(''); } .first{clear:both;margin-left:0}.one-third{width:31.034482758621%;float:left;margin-left:3.448275862069%}.two-thirds{width:65.51724137931%;float:left}form.ebook-styles .af-element input{border:0;border-radius:0;padding:8px}form.ebook-styles .af-element{width:220px;float:left}form.ebook-styles .af-element.buttonContainer{width:115px;float:left;margin-left: 6px;}form.ebook-styles .af-element.buttonContainer input.submit{width:115px;padding:10px 6px 8px;text-transform:uppercase;border-radius:0;border:0;font-size:15px}form.ebook-styles .af-body.af-standards input.submit{width:115px}form.ebook-styles .af-element.privacyPolicy{width:100%;font-size:12px;margin:10px auto 0}form.ebook-styles .af-element.privacyPolicy p{font-size:11px;margin-bottom:0}form.ebook-styles .af-body input.text{height:40px;padding:2px 10px !important} form.ebook-styles .error, form.ebook-styles #error { color:#d00; } form.ebook-styles .formfields h1, form.ebook-styles .formfields #mg-logo, form.ebook-styles .formfields #mg-footer { display: none; } form.ebook-styles .formfields { font-size: 12px; } form.ebook-styles .formfields p { margin: 4px 0; } Get The Full Henry Singleton Series in PDF Get the entire 4-part series on Henry Singleton in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues (function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';}(jQuery));var $mcj = jQuery.noConflict(true); Q3 2022 hedge fund letters, conferences and more   Find A Qualified Financial Advisor Finding a qualified financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you're ready to be matched with local advisors that can help you achieve your financial goals, get started now. This is where having data and knowing how to use it comes in handy. Being able to look at human workplace performance from a data-driven perspective is a game-changer. Data allows you to see clearly which key performance indicators (KPIs) are relevant when recruiting, upskilling, and retaining team members. However, figuring out how to make sense of the proliferation of data at your fingertips can seem overwhelming. Two Story takes away the confusion and makes it possible to ethically process, analyze, and interpret data to extract insights and empower the people who power your business. Two Story: Shaking up the World of Workplace Performance Analytics In the area of performance analytics, Two Story has arisen from the startup world as a disruptor. The company was founded by Certified Professional Behavior Analyst and Certified Forensic Interviewer Kerry Goyette. Goyette started Two Story to leverage artificial intelligence technologies to connect people data to business outcomes. She leads the company as CEO along with Michael Mueller and Bryce Murray, Ph.D. This cross-functional team brings expertise in behavioral science and applied artificial intelligence. Two Story merges behavioral science with AI to help companies make quality people decisions at scale and accelerate team performance. The company's proprietary eXplainable algorithm is designed to process disparate datasets and provide insights to help organizations and their personnel thrive. Two Story: Making Use of Four Types of Analytics What's the major power beyond Two Story's innovative algorithmic solution? It brings together four major types of analytics used for workplace performance evaluations. These include descriptive analytics, diagnostics analytics, predictive analytics, and prescriptive analytics. Descriptive analytics are those that are fairly easy to calculate and identify. For instance, you can probably see that your sales team's conversions are down for Q2. Though this information is useful, it doesn't have any kind of context. You don't actually know why the salespeople's leads aren't converting and signing contracts. You could take a guess, but you might be wrong. This is where diagnostics analytics can flesh out a fuller picture. Diagnostics analytics look at the "why" behind descriptive analytics. Perhaps during Q2, your sales team members were given more subpar than high-quality leads. Consequently, conversions plummeted because your sales team was working with inadequate leads. Now that you know this, you can use predictive analytics to look forward. You might say, "Well, if we don't improve our lead quality, our Q3 conversions will continue to be low." From that point, you can apply prescriptive analytics to come up with an action to resolve your problem. In this case, the answer would be to work with marketing to put more money into sources that generate high-quality leads. Two Story's breakthrough performance analytics tool offers a platform to collect, measure, and analyze countless data points like the aforementioned. As a leader, you can therefore use Two Story's product to get closer to the "why" of your data. Remember: Data can be deceptively one-sided. Being able to dig deeper gives you more control over how you use your data to help your operations and success. A Two Story Client Story Driving greater impact by digging deeper into human performance data was the goal of a successful Construction SaaS company. The organization employs teams across the country and wanted to understand how to make better hiring decisions. Specifically, executives were interested in knowing their best general managers' characteristics and skills. That way, they could scale their team with excellence. Two Story decoded the key performance behaviors of the company's general managers that were spread across 115 locations. This occurred through a deep dive into the financial performance of each general manager. Two Story's algorithm analyzed more than 50 behavioral science attributes, designed 70+ different machine learning and data fusion techniques, and objectively evaluated the contribution of each model for driving financial performance. The results of the partnership were compelling. The organization was not only able to expand its talent pool during a tough labor market but it improved job fit and the financial performance among its general managers. In the future, the organization plans to use Two Story's findings to continue hiring high-performance general managers. The company estimates that general managers with at least a 67% job fit can deliver net earnings 420% above their previous average. Coaching and Training: Much Improved With Two Story's Assistance Knowing the "why" behind data and being able to hire confidently are just two benefits behind Two Story. Another is the ability for businesses to get more out of their internal training and coaching programs. As Gartner research shows, effective, pragmatic coaching can improve worker engagement by 40% and lessen the risk of turnover. Two Story makes it possible to know which skills to focus on for maximum employee performance and development. For instance, you could have the team collect relevant assessment data and your preferred business outcomes. Using AI, the Two Story team could then set benchmarks for each position and pinpoint the profiles of high performers. Using those benchmarks as your guides, you could then construct a unique, robust training program to advance everyone's performance. More than anything else, Two Story is proving that we're only beginning to tap into AI's possibilities and opportunities. We're a step closer to being able to truly optimize human potential at work. Article by Brad Anderson, ReadWrite.....»»

Category: blogSource: valuewalkNov 4th, 2022

See the presentations that cutting-edge biotech companies have used to raise millions from top investors

From 64x Bio to Faeth Therapeutics, here are the presentations that biotechs used to win over investors and raise millions to grow their companies. Researchers inside Moderna's lab in Norwood, Massachusetts.Franco Sacchi/Insider Biotech startups have raised billions of dollars in an effort to transform medicine. Despite an economic downturn, biotechs are still getting interest from investors. Here are the presentations that biotechs used to win over investors and raise millions. Over the past few years, the pandemic fueled a massive boom in biotech investing. Funding for biotech companies soared in 2021 to nearly $47 billion — a record for the industry.This year has marked a slowdown. As the global economy becomes more uncertain, venture capitalists have become cautious about investing in startups of all kinds — including biotech firms. Some private biotechs are delaying going public, and even preparing to raise down rounds. Despite the market downturn, some companies are still raising sizable funding rounds. One key to these is a great pitch deck, the presentation that companies use to solicit funding from investors. Pitch decks, also known as slide decks, usually lay out the company's history, its achievements, and where it's heading.Insider rounded up all the biotech pitch decks we've published, from those seeking early-stage funding to presentations for late-stage rounds, that have helped companies raise money from investors. In seed and Series A funding rounds, startups raise money to test their ideasSeed and Series A funding rounds come at the early stages of a biotech company. The company may have an idea or some preliminary clinical data, but it still needs to vet its science more thoroughly. Some companies, such as 64x Bio, have newly identified a problem — in 64x Bio's case, drug-manufacturing bottlenecks — and have an idea for a plan that could fix it. This is the 10-slide presentation the company used to quickly raise $55 million.Other startups, like the cancer-metabolism company Faeth Therapeutics, have shown promising results in lab tests and mice but not yet in humans. Check out the company's 17-slide presentation it used to raise $47 million.Oftentimes, companies raising early funding rounds, like the biosensor company Monod Bio, hope the money can fund trials that will prove their science works. Monod used this 12-slide pitch deck to raise $25 million from investors.Read more:See the 11-slide presentation that sold General Catalyst on a 21-year-old founder's at-home lab-testing platform for Latin AmericaSee the 27-slide presentation a secretive biotech startup backed by Sean Parker used to raise $40 million and 'open a new universe' in cancer immunotherapyThis 10-slide presentation convinced top VC firm NEA to invest $20 million in its first clinical-operations startupSee the presentation microbiome startup Seed Health used to raise $40 millionBy Series B funding rounds, biotech companies are trying to start human studiesBy Series B rounds, startups are often raising large sums of money and focused on growth. Many times, the companies will use new capital to hire more employees or continue to bring drugs through clinical development. For instance, the Belgian biotech AgomAb told Insider it planned to use its new funds to extend the company's cash runway into 2024. Here's the 21-slide pitch deck the company used to raise $144 million from investors.And the genetics startup Camp4 used an 18-slide pitch deck to raise $100 million and plans to start human testing in 2023. The cancer startup Affini-T Therapeutics also plans to have two treatments in human testing in 2023. Here's the 24-slide pitch deck the company used to raise $175 million from investors like Leaps by Bayer. Read more:See the 13-slide pitch deck a biotech used to raise $120 million and write the next chapter in mRNA medicinesSee the pitch deck a doctor used to sell his vision for an entirely new way of testing experimental drugs and win a $250 million valuationLate-stage funding rounds prepare biotech startups to go public Series C, D, and even E funding rounds can help private biotechs get a reserve of cash before a public debut. The presentations used in these rounds often highlight the company's science and show investors what lies ahead. The funding rounds, such as Moderna's pitch to investors in 2017, can come shortly before plans to go public. Moderna made its public debut in 2018.Some companies, like the cell-therapy startup Aurion, are almost ready to file for regulatory approval in certain countries. Here is the 24-slide pitch deck the company used to raise $120 million and prepare for regulatory approval in Japan.  In late-stage funding rounds, the investors might also be different or used to backing bigger companies. This is the 15-slide presentation that Deep Genomics used to secure $180 million funding from blue-chip investors, including SoftBank. Read more:See the 14-slide pitch deck a French biotech just used to raise $86 million to pursue a twist on one of the hottest ideas in cancer researchSee the 24-slide pitch deck a biotech startup used to sell investors on a new approach to AI in medicine and raise $110 millionRead the original article on Business Insider.....»»

Category: dealsSource: nytSep 9th, 2022

54gene’s CEO Abasi Ene-Obong Wants to Fix the Racial Imbalance in Health Data

54gene's CEO Abasi Ene-Obong is on a mission to right the sharp racial imbalance in global health data. Born and raised in the Nigerian port city of Calabar, Abasi Ene-Obong remembers the exact moment that changed his life’s direction. Sitting in an introductory genetics class at medical school, in 2003, he heard the professor say that African genetic samples comprised less than 3% of health data bases in the world, creating a stunning vacuum in its ability to detect diseases and develop effective treatments for hundreds of millions of people. Ene-Obong ditched his plan to become a doctor, and instead left for London, and later Los Angeles, to study genetics, finally earning a Master’s degree in business focusing on the bioscience industry, at the Keck Graduate School in California, and a Ph.D. in cancer biology at the University of London. [time-brightcove not-tgx=”true”] With that, he launched 54gene in 2019—named for the 54 countries in Africa—with the mission to right the sharp racial imbalance in global health data. Headquartered in Lagos, Nigeria, and Washington, D.C., the startup was on TIME’s 2019 list of best health innovations. Three years on, Ene-Obong, 37, says every part of the mission has proved hugely challenging, from raising venture-captial funds to explaining to Big Pharma companies what 54gene is trying to do. TIME met Ene-Obong in Paris in June to discuss how his company intends to grow its business, make money and the process of winning over investors—and the health problems at stake. This interview has been condensed and edited for clarity. (For coverage of the future of work, visit TIME.com/charter and sign up for the free Charter newsletter.) What is the major problem you are trying to solve? This is a problem that affects everyone across the world. We’re all faced with new diseases, and even current diseases, like cancers and cardiovascular diseases, and there’s a need to find cures, with advancements in bio-computing, and AI and genomics. Because of the maturity of various tech verticals, where most groups are beginning to look at genetics, that could mean better diagnostics, and safer and more effective drugs for diseases. In order for us to understand human biology, we can’t just look at one group of people and assume that group represents all people. Right now most of the genetic [data in] databases across the world is Caucasian. I see 54Gene’s website says only 3% of the world’s genetic databases come from African genes. Actually it’s less than 3%, That is something my company is trying to solve. Africans represent the most diverse population on Earth, and what that means from a genetic standpoint is that lots of what we call variants that we need to understand, what we’re looking for is just differences. We’re not only talking between Africa and Caucasian, but also between [for example] Nigerians and Cameroonians. Nigeria has more than 300 ethno-linguistic groups. I am mixed, Efik and Igbo, from Calabar, which was one of the biggest exporters of slaves. Is this vacuum the fault of Big Pharma? Or is it African countries and governments that have simply not collected genetic data? It’s everybody’s fault. It’s both the fault of governments not prioritizing this, in many cases, not even understanding the need for this. And it’s also the fault of Big Pharma. Big Pharma has been opportunistic. They’ve gone to where the data exists. It has not really been their job to produce the data. But because of their role in the ecosystem, they could be a voice to really advance this part of medicine. I would put quite a lot of the fault on the lack of research and development in Africa. I want to make sure we are being honest with ourselves. If we as Africans take the initiative and the leadership in this, then others will come to the table. There was a lot of talk during the pandemic about vaccine nationalism and about African governments being cut out of any fair distribution. Is this part of the same problem—that Western pharmaceutical companies are basically rapacious? I’m not an apologist for the West, but I think we need to take more ownership and more action. You don’t have to match the West and put $2 billion into COVID, but you can put a portion of your budget. What we’re seeing is that they [African governments] were not even putting in that. Most of health care in Africa has typically been funded by international donors. So African governments have not owned their own health care. They have lots of international donors who put in the money and dictate the agenda for how funds should be used. And so after decades and decades of that type of behavior, they have to unlearn, and practice healthcare in the way it should be practiced. Now we’re beginning to see that in certain governments. What’s 54gene’s business model? And how do you partner with Big Pharma and other entities? Our goal is not so much to create the data and have anybody buy it. That would not be responsible. We have to fix systemic issues, where people come in [to Africa] to pay for samples, take the samples to their countries, all outside Africa, do the research and development outside, make the drugs, and they never come back to Africa. Right now, it takes 10 to 20 years for a drug launched in the U.S., or France, to come to Africa. Our business model is one that I believe is more inclusive and sustainable, and has Africans in mind. Rather than building a data set and sending it out, we are doing the R&D work, sometimes in partnership with pharma companies, the goal being that we will develop drugs or our data will be used to improve diagnostics for Africans and non-Africans. How are your discussions going with big pharmaceutical companies? We do have works in progress with a few pharmaceutical companies, both U.S. and European. When you talk to CEOs, is the work you’re doing something they understand, or is it a jump for them? We have some that understand the need to do this type of work in Africa, such as doing the [genetic] sequencing on the continent, with which we’ve built a sequence in the lab so that we don’t have to send them abroad, or doing the clinical trials in Africa such that African patients can also get access to innovative drugs very early on. So we see that some of these companies get it. A majority of them do not get it, because the majority of them are still looking at old business models. They want access to biological samples, to do the research and make whatever decisions the boardroom decides. Do you see health crises, or disease, where the outcome would have been different if Africa had this kind of genetic data? With COVID-19, we know we should have very robust surveillance systems. But in order to do that, you need to have the technical capability and infrastructure. Africa lacks quite a lot of that. Again, that is one of the things we are solving. But you know, there are 54 countries and 1.4 billion people. We could do much, much better. And yes, it could help prevent some infectious diseases. But people are not yet calling out the rise in non-infectious diseases, and we are seeing that in hospitals: Rises in cancer cases and cardiovascular disease cases. Most public funders have prioritized infectious diseases like HIV, tuberculosis, malaria. That’s where all the money has gone to. That has led to a lack of development in this non-infectious disease care management. I don’t think this is really understood. Are you saying that basically, to treat diseases like cancer, heart disease and diabetes, Africans might require treatment specific to them? In a lot of cancers, with the mutational drivers, most of our understanding is based on studies done in purely Caucasian populations. There was a study a year ago at the University of Chicago where they looked at breast cancers amongst Yoruba women, which found there was a different gene mutation causing a number of cases. The women got more severe breast cancer in their 40s. The drugs we’ve been using to treat breast cancer, and the diagnosis, have not really looked for this mutation. How hard has it been for you to raise funds for 54gene? We raise funds mostly through venture capital funding, where we give some equity, for investments. As of last year, we had raised $45 million. We are attracting very good investors. I see the company becoming a major player in the health tech space, measured by impact, rather than the monetary value. The work we are doing is going to improve health outcomes in various countries in Africa, covering hundreds of millions of lives, potentially. Globally, it’s going to help inform how diseases are looked at, how new drugs are developed. What is the potential impact on Black Americans? The work is going to impact all people of African origin, whether they are in Africa, France, the U.K., or the U.S., Brazil, or the Caribbeans. Many of them came from West Africa. We know Nigeria contributed about 25% during the slave trade. And we still see more Nigerians leaving. As the world gets more diverse, this is only going to get even more important. And then, of course, Nigeria will soon have more people than the U.S. Yes. And Africa will soon have more people than Asia. Big Pharma is notoriously focused on its bottom line. What do you say when they ask, ‘what is in it for us?’ Quite a few things are in it for them. One is it’s going to improve the pipeline of new products, not just products sold in Africa, but also globally. We’re not saying that your entire focus should be Africa. We are saying you can include Africa in your focus, and it could also impact your bottom line significantly. I’ll give you an example. There is a drug used to treat bad cholesterol. A lot of the insight for the work came from Africans, because the drug targets a rare mutation, that is more common in African populations. The discovery came from African populations in the U.S., actually. At what moment did you suddenly think to yourself ‘this is what I should do?’ A lot of it was serendipity. I was studying medicine as an undergraduate in Nigeria. I saw how genetics held the possibility of finding cures for rare diseases like Huntington’s and sickle cell disease. I got very interested at that age in doing genetics. By the time I was doing my Ph.D., I realized that I wanted to be running a company that was global, but also provided a platform for Africans to contribute globally to research and healthcare. In 2013, I moved to LA. I worked in the U.S. as a management consultant for pharmaceutical and biotech companies. The first sets of data coming out showed how diverse African populations were, and the lack of that data. So I knew that with my educational background and my work experience, and being born in Nigeria, that I could solve some of this problem. And so I went back to start it. Why does 54gene have a Washington base? What’s the purpose of that? It’s a global company. There are a lot of people, Africans and non-Africans, who want to contribute to this mission because it affects all of us as human beings. Right now we have over 100 people in Nigeria, and nearly 30 in the U.S. We’re sitting here at VivaTech, a tech conference in Paris, and there’s been a lot of talk for a long time about the tech industry being overwhelmingly white. How has your experience been? People solve what they know. It is the same for investors: Investors invest in what they know, and what they connect to. When you don’t have a diverse group of people in key decision-making positions in the tech industry, you are not going to get them to invest in Black businesses, or businesses from diverse communities, because they want to put their money in what they understand. We need to have more diversity in the VC [venture capitalist] offices. Investments are emotional, you have to have an emotional connection. I’m assuming when you are dealing with VCs it is mostly white men, correct? Yes. I have reason to believe investment is emotional, from my own personal experience. It could mean I am connected to the problem, or connected to the person who is solving the problem. One way we solve that problem is having people who are of diverse ethnic groups and experiences. When I talk to U.S. or U.K. or European VCs about the market in Africa and how it’s growing, many of them have never been to Africa. Many of them still have the same pictures that you see on TV, of somebody begging, of donating to charity. One investor meeting I had, he started mentioning what he does for charities. As I started talking, he was interjecting all the time. Some of his colleagues were getting uncomfortable. At some point I said, I didn’t come here to be insulted. I would rather not take your money. He had to take a step back and his colleagues apologized. So, for an investor like that, there is no sense that maybe there could be a return on the investment? When he stopped talking and started listening, he ended up saying, ‘oh this is this is actually cool.’ But that was an experience I do not want to repeat......»»

Category: topSource: timeAug 8th, 2022

Everything you need to know about the biotech market"s meltdown — and how companies can survive it

Biotech has been hit hard by the recent downturn. Here's what you need to know about how public and private biotech companies are struggling. Mark Foley, CEO of Revance Therapeutics, Cameron Durrant, CEO of Humanigen, Henry Ji, CEO of Sorrento Therapeutics, and Nick Leschly Former CEO of Bluebird BioRevance Therapeutics; Humanigen; Sorrento Therapeutics; Wendy Maeda/Getty Images; Savanna Durr/Insider The biotech market has been hit particularly hard by the current market downturn. In order to survive, public companies are contemplating M&A and liquidation. Private companies are hoarding cash and thinking about taking on debt. 2022 has been a rough year for the economy — and the biotech market was hit particularly hard.The SPDR S&P Biotech ETF, a leading biotech index, has fallen 35% since the beginning of 2022 — and is 45% lower than June of last year. Public and private biotech companies have been scrambling to adjust to the market downturn, and some have had more success than others. Some public companies are on the verge of bankruptcy, or debating whether liquidation or M&A are strategies that could give shareholders back some cash. Meanwhile private companies are delaying IPOs and hoarding cash, hoping to hunker down as the storm passes.Insider has spoken to company executives, analysts, and investors to determine how bad this current biotech downturn is, and the different strategies companies can take that might just allow them to pull through. Public companies are running out of cash — and some risk going bankruptWhen it comes to keeping a public company afloat, cash is critical. Companies running short on cash usually feel the worst effects of a market downturn, and this can be especially true for a company that has a high cash-burn rate. In May, analysts at Jefferies looked at company burn rates and found that 18 public biotech companies might not have enough cash to continue operations for much longer. For other companies, there are more complex factors at play. Economic conditions, competitors, legal battles and more can all contribute to whether or not a company survives. Companies that are on shaky ground need to announce a "going-concern" warning — a note that company executives have substantial doubts about staying in business. With the help of accounting data firm Audit Analytics, Insider identified 13 large drug companies that issued these warnings.When it comes to which companies will be able to pull through and which will go bankrupt, ultimately only time will tell. But we have some hints: A top credit-risk firm shared data with Insider showing the 10 biotech companies most likely to go bankrupt.Read more: Top biotech analysts say these 18 companies are set to run out of cash within a yearInsider identified 13 drug companies that are in a dangerous financial position and struggling to survive through 2022A top credit-risk firm says these are the 10 biotech companies most likely to go bankruptSome companies may turn to restructuring, M&A, and liquidation Public companies facing bankruptcy and other financial struggles have several ways they can try to stay afloat, and even give some money back to shareholders. One of the most common solutions is restructuring the company — often in the form of layoffs. After gene-therapy biotech Bluebird Bio warned investors that it had substantial doubts about continuing operations, the company decided to lay off 30% of its employees in an effort to reduce costs. Another option companies have: M&A. Pharma giants ended last year with $500 billion in cash, and that cash could be a lifeline to smaller, struggling companies. It's a win-win situation: small biotechs get a bailout, while big pharma companies can add new treatments to their pipelines. Insider found that 10 companies are most likely to become takeover targets this year. One company from the list, Biohaven, is already in the process of being acquired by pharma giant Pfizer. Other companies that want to find similar partnerships should do their best to become attractive targets to big pharma by focusing on science and the patients, four top dealmakers said. For companies that are truly struggling, some investors have proposed a dramatic solution: liquidate entirely, and give cash back to shareholders. For companies that are trading at valuations below their cash level, liquidation could be an unconventional win-win situation — investors get a return on their investment, and CEOs can get cash to start a new venture. Read more: Gene-therapy biotech Bluebird Bio is set to lay off 30% of the company after warning it could struggle to survive through 2022Big Pharma will have $500 billion to spend in 2022 and is hungry for M&A. Here are the 10 biotechs analysts say are takeover targets.4 Big Pharma dealmakers share the 2 overlooked elements that biotech companies need to be a great partner and close dealsInvestors are starting to push troubled biotechs to liquidate — and it might not be a bad ideaPrivate companies are hoarding cash and looking for deals while delaying IPOsPrivate companies have a different strategy when it comes to outlasting the downturn. In normal times, some private companies might be in the process of going public — but that's unlikely to happen often this year. Instead, biotech VCs say that companies need to grab as much money as possible and invest in strong leadership to survive the market downturn. One top VC said that going public right now would be "insane."In fact, despite biotech valuations hitting a 10-year high in 2021, some companies might have to conduct "down rounds", which occur when startups raise capital at a lower valuation than they previously held.There are other ways that private companies can get cash. Some experts have suggested that companies could carefully take on some debt  — just enough to survive the next three to six months. They can also try to create partnerships on future drug royalties, or come up with a hybrid financing model. Read more: Biotech startups are grabbing more cash and bracing for a public-market meltdown: 'Everyone sees the storm'A top biotech VC shares the 3 criteria startups need to survive the market meltdownBiotech valuations hit a high last year, but a top banker from JPMorgan says investors need to prepare for rare 'down rounds'The biotech market is melting down. Here are 3 unconventional ways startups can raise money without relying on venture capital.Companies in hot fields like mRNA and cancer are still raising substantial fundsNot all private companies are struggling, however. Some continue to raise millions of dollars, especially in the fast-growing areas of mRNA and cancer. ReCode Therapeutics recently raised $120 million to continue its work in mRNA, while cell therapy startup Affini-T raised $175 million to fight cancer. See more examples of successful funding pitches below.Read more: See the 14-slide pitch deck a French biotech just used to raise $86 million to pursue a twist on one of the hottest ideas in cancer researchThe 24-slide presentation a first-time CEO used to raise $120 million to cure blindnessSee the 17-slide presentation a tiny biotech used to raise $47 million for a new way of fighting cancer with nutritionRead the original article on Business Insider.....»»

Category: worldSource: nytJul 8th, 2022

The 5 most popular pitch decks, according to our readers

Business Insider has obtained hundreds of pitch decks used by startups to persuade VCs and other investors to fund them. These are the most popular, according to our readers. Tom Werner / Getty ImagesBillions of dollars in venture capital flow every year to startups that can articulate their visions in a way that makes investors see dollar signs.Startups do this by creating pitch decks, or slideshows that meld imagery, hard data, and storytelling to help investors see their potential.For years, Insider has been publishing individual pitch decks to give readers an inside look at startups' business strategies and how they wooed investors to back them.These are the 5 most popular, according to our readers. You can browse our entire library with more than 700 decks here, including companies like Airbnb, Postmates and Uber.How to build a pitch deck that will wow investorsWith a potentially more narrow investment funnel pouring into startups, the necessity for founders to deliver a compelling business case for funding is all the more crucial.fizkes/ShutterstockThey tell you not to judge a book by its cover — but investors will absolutely be using your pitch deck to evaluate your company's potential, so you'll want to make a stellar impression.The past two years have seen record increases in venture capital funding. Investors poured $329.5 billion into funding US-based startups last year, nearly double 2020 totals, according to data and research company Pitchbook. But, analysts warn that the two-year spurt is on the decline. Early data shows the first quarterly fundraising dip in nearly two years, with startup investments declining by 11% in the first quarter of 2022, according to Crunchbase.With a potentially more narrow investment funnel pouring into startups, the necessity for founders to deliver a compelling business case for funding is all the more crucial, according to experts. To that end, we asked a series of successful entrepreneurs and investors for their best advice on creating an impressive pitch deck.You can read the full guide here for crafting your own deck. Three Ships Beauty.Courtesy of Three Ships BeautyConnie Lo and Laura Burget, both 28, are cofounders of Canadian skincare brand Three Ships Beauty.They used 4,000 Canadian dollars ($3,128) of their savings to start the company in 2017.Their first product was coconut- and essential oil-infused makeup remover wipes, which they made in Lo's apartment and sold at farmer's markets in Toronto.During the day, the duo worked full time in corporate sales, and during evenings and weekends, they brainstormed ideas and packaged products until 3 a.m. By September 2018, they'd quit their jobs, moved production to Lo's parents' basement, and expanded the line to 18 products. The brand became a fast favorite with magazine editors and retailers, but when the pandemic hit, the retail shops selling their stock closed, shipping costs rose, and then the bestselling Radiance Day Cream went out of stock, as one of the ingredients came from Italy. Here's the pitch deck they used to raise $1 million in two weeks from the CEO of Dyson and others.See the presentation that convinced 2 billionaires and Dr. Oz to invest in a new way of helping doctors care for patients at home100Plus CEO Ryan Howard.100PlusKeeping tabs on patients' health at home has become a surging business during the coronavirus pandemic.With the virus spreading, physicians needed to find ways to make sure their patients' health stayed in check while limiting in-person visits. They turned to virtual consultations and digital tools that could be used at home to track blood pressure, diabetes, and lung conditions like emphysema and COPD. Upstart primary care offices and major hospitals have been quick to adapt to telemedicine and remote monitoring, but smaller doctors' offices have struggled to bring the costly and complex technology into their practices. 100Plus, a San Francisco remote monitoring startup, thinks its approach could help clinicians navigate the world of remote healthcare.100Plus offers remote patient monitoring services that are easy to set up and costs patients little or nothing. Instead, the company signs contracts directly with primary care physicians.100Plus ships blood pressure monitors, pulse oximeters, digital scales, and other devices to patients' homes, preprogrammed to operate as soon as the patient opens the box. The devices send the data they collect back to their physician's office. This is the deck that 100Plus used to raise $25 million that valued the company at $100 million from private equity giants Henry Kravis and George Roberts of KKR, as well as self-help guru Tony Robbins, television personality Dr. Mehmet Oz and other angel investors. Here is the 23-slide presentation a former Marie Claire editor-in-chief used to get millennial men to invest in a startup that treats menopause symptomsAlloyIn 2019, Anne Fulenwider, a former Marie Claire editor-in-chief, was surprised while speaking with her friend Monica Molenaar, who'd had her ovaries removed as a preventive measure against breast cancer. The procedure essentially kick-starts menopause Fulenwider explained to Insider, but Molenaar hadn't been able to find suitable options for treating her new symptoms, like hot flashes, for nearly five years."I couldn't believe that it took her five years to figure it out," Fulenwider told Insider. "I just thought we have to fix this."In 2020, Fulenwider, 49, and Molenaar, 47, cofounded Alloy, a direct-to-consumer digital-health company that treats menopause symptoms.They used this presentation raise $3.3 million in seed funding from PACE Healthcare Capital and Kairos HQ, where the two women had incubated the company.Read the pitch deck 2 founders used to land $59 million to help barbershops run their sales and bookings more smoothlySquire cofounders Dave Salvant and Songe LaRon.SquireIn 2014 when longtime friends Dave Salvant and Songe LaRon starting thinking about building a business together, they kept coming back to one enterprise that meant a lot to them both: barbershops. The pair reminisced about visiting barbershops nearly every week of their lives and observed that while their hairstyles may have changed over the years, barbershop's operations hadn't: Customers typically called for an appointment and paid in cash. "There were a lot of pain points for professionals and we figured there was a real opportunity that no other tech companies were addressing," Salvant said. In 2015, the cofounders launched Squire, a platform that handles bookings, payment, analytics, and other business services, for barbershops.When the pandemic hit, the New York City-based company waived subscription fees and started offering gift card services so customers could still support their local barbers — the business sold about $30,000 in gift cards, the cofounders said. They shared the pitch deck that helped them raise $59 million. See the 30-slide presentation a women's healthcare startup used to raise $100 million one year after losing all its revenue 'overnight' because of COVID-19Tia cofounders Felicity Yost and Carolyn Witte.TiaThe women's health startup Tia lost all of its revenue "overnight" when the pandemic shut down its in-person clinic in March 2020, according to cofounder and CEO Carolyn Witte.Before the pandemic, Tia was building healthcare clinics for women. Its first clinic was in New York City and offered primary-care services for a $150 annual membership fee.Like many other healthcare companies, Tia started offering virtual care to fill the gaps. But Witte never gave up on reopening the clinics. Instead of going "all in" on virtual care, she said Tia embarked on a hybrid model that included virtual check-ins with in-person appointments once it was safe to do so.That strategy felt contrarian at the time, Witte said.Here is the 30-slide presentation that Witte used last year to raise $100 million in Series B funding in just three weeks.Read the original article on Business Insider.....»»

Category: smallbizSource: nytMay 10th, 2022

3 Best Life Sciences Stocks to Buy Now

As soon as you saw that there was money to be made on COVID-19 vaccinations, did you jump on board and buy COVID-19 vaccine companies? Why not expand your thinking beyond COVID-19? (However, it’s important to remember that companies like Moderna have other promising vaccines in the pipeline, such as a cytomegalovirus vaccine (mRNA-1647), a […] As soon as you saw that there was money to be made on COVID-19 vaccinations, did you jump on board and buy COVID-19 vaccine companies? Why not expand your thinking beyond COVID-19? (However, it’s important to remember that companies like Moderna have other promising vaccines in the pipeline, such as a cytomegalovirus vaccine (mRNA-1647), a respiratory syncytial virus (RSV) vaccine for adults 60 and over (mRNA-1345) as well as its Zika vaccine (mRNA-1893). if (typeof jQuery == 'undefined') { document.write(''); } .first{clear:both;margin-left:0}.one-third{width:31.034482758621%;float:left;margin-left:3.448275862069%}.two-thirds{width:65.51724137931%;float:left}form.ebook-styles .af-element input{border:0;border-radius:0;padding:8px}form.ebook-styles .af-element{width:220px;float:left}form.ebook-styles .af-element.buttonContainer{width:115px;float:left;margin-left: 6px;}form.ebook-styles .af-element.buttonContainer input.submit{width:115px;padding:10px 6px 8px;text-transform:uppercase;border-radius:0;border:0;font-size:15px}form.ebook-styles .af-body.af-standards input.submit{width:115px}form.ebook-styles .af-element.privacyPolicy{width:100%;font-size:12px;margin:10px auto 0}form.ebook-styles .af-element.privacyPolicy p{font-size:11px;margin-bottom:0}form.ebook-styles .af-body input.text{height:40px;padding:2px 10px !important} form.ebook-styles .error, form.ebook-styles #error { color:#d00; } form.ebook-styles .formfields h1, form.ebook-styles .formfields #mg-logo, form.ebook-styles .formfields #mg-footer { display: none; } form.ebook-styles .formfields { font-size: 12px; } form.ebook-styles .formfields p { margin: 4px 0; } Get The Full Henry Singleton Series in PDF Get the entire 4-part series on Henry Singleton in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues (function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';}(jQuery));var $mcj = jQuery.noConflict(true); Q4 2021 hedge fund letters, conferences and more If you're reluctant to put all your eggs in the vaccine basket, why not consider life sciences companies with a broader scope? Life sciences companies concern themselves with the development and manufacture of pharmaceuticals, biotech food and medicines (including food processing), medical devices, cosmeceuticals, and more. It's truly mind-boggling what life sciences stocks have to offer, so let's dive into a quick explanation of life sciences stocks and suggest three stocks to add to your list. Why Buy Life Sciences Stocks? Think of life sciences stocks as spanning the entire range of sciences — biochemistry, biotechnology, botany, microbiology, molecular biology, physiology, zoology, and more. When you invest, a multitude of opportunities spread before you. This wide range of stocks available to you includes companies that develop and market products such as pharmaceutical companies that develop medicines, medical device companies that manufacture and market surgical tools, biological products, diagnostic systems and so much more. The global life science analytics market size was valued at $8.3 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.7% from 2022 to 2030, according to Grand View Research — just another great reason to consider life sciences stocks. 3 Life Sciences Stocks to Pop into Your Portfolio Let's take a look at three stocks to add to your portfolio. Thermo Fisher Scientific Inc. (NYSE:TMO) Thermo Fisher Scientific Inc., based in Waltham, Massachusetts, is a gargantuan, diversified life sciences company. Thermo Fisher Scientific Inc. has a complex portfolio of life sciences analytical instruments, specialty diagnostics, and laboratory products. The company produces reagents, instruments, and consumables for research and diagnosis of infections and diseases as well as instruments, consumables, software, and services for production lines, research, industrial markets, and clinical laboratories. The company creates lyophilized immunodiagnostic reagent kits as well as calibrators, controls, and calibration verification fluids, allergy, and asthma tests, and EliA for autoimmunity tests, laboratory refrigerators, and freezers, ultra low-temperature freezers and cryopreservation storage tanks, water analysis instruments, laboratory plastics, and pharma services. The company's products are distributed through a direct sales force, customer-service professionals, electronic commerce, third-party distributors as well as catalogs. The company reported strong results in the fourth quarter due to growth in its base business and $2.45 billion in COVID-19 response revenue. Q4 revenue was $10.70 billion and GAAP diluted earnings per share (EPS) was $4.17. Q4 adjusted EPS was $6.54. Full-year 2021 revenue grew 22% to $39.21 billion and GAAP diluted EPS increased 22% to $19.46. Full-year adjusted EPS also increased 28% to $25.13. Abbott Laboratories (NYSE:ABT) Abbott Laboratories, headquartered in North Chicago, Illinois, develops, manufactures, and sells health care products all over the world. It creates treatments for a long list of diseases, including pancreatic exocrine insufficiency, irritable bowel syndrome, biliary spasm, intrahepatic cholestasis, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, influenza vaccine, and more. It also develops and manufactures systems for extraction, purification, and preparation of DNA and RNA, cartridges for testing blood, testing for HIV, SARS-CoV-2, influenza A and B, RSV, strep A, and more. The company also manufactures pediatric and adult nutritional products and heart devices for the treatment of cardiovascular diseases as well as diabetes care products. The company continues to develop new products, including several in fast-growing markets. Q4 sales grew 7.2% and organic sales grew 7.7% in Q4 2022. Global COVID-19 testing sales helped boost Abbott Laboratories' growth to $2.3 billion in Q4. With the exemption of COVID-19 testing-related sales, Q4 sales growth of 9.6% and organic sales growth of 10.3%. Full-year 2021 sales grew 24.5% and organic sales grew 22.9%. In addition, full-year 2021 GAAP diluted EPS from continuing operations grew 58.2%, and adjusted diluted EPS grew 42.7%. CRISPR Therapeutics AG (NASDAQ:CRSP) CRISPR Therapeutics AG, headquartered in Zurich, Switzerland, is a gene-editing company that innovates to create gene-based medicine for serious human diseases based on changes to genomic DNA. The company's lead product candidate is CTX001, a gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110 which targets positive malignancies as well as CTX120, an investigational therapy targeting B-cells as well as CTX130 for the treatment of solid tumors and hematologic malignancies. The company also develops regenerative medicine programs to treat muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strong partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte Inc., Nkarta Inc., and Capsida Biotherapeutics. Cash, cash equivalents, and marketable securities were $2,379.1 million as of December 31, 2021, compared to $1,690.3 million as of December 31, 2020. Total collaboration revenue was $12.3 million for Q4 2021 compared to $0.2 million for Q4 2020 and $913.1 million for year-end 2021, compared to $0.5 million for the end of the year in 2020. R&D expenses were $134.5 million for Q4 2021 compared to $82.4 million for Q4 2020, and $438.6 million for the end of the year, compared to $266.9 million for the year at the end of 2020. Net loss was $141.2 million for Q4 2021 compared to $107 million in Q4 2020. Net income was $377.7 million at the end of 2021 compared to a net loss of $348.9 million at the end of 2020. Ready to Dive into Life Sciences Stocks? When you'd like to consider looking into life sciences stocks, seriously consider diving in! There's a lot of potential and possibilities in this sector. Should you invest $1,000 in Thermo Fisher Scientific right now? Before you consider Thermo Fisher Scientific, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list. While Thermo Fisher Scientific currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys. Article by Melissa Brock, MarketBeat Updated on Apr 8, 2022, 6:08 pm (function() { var sc = document.createElement("script"); sc.type = "text/javascript"; sc.async = true;sc.src = "//mixi.media/data/js/95481.js"; sc.charset = "utf-8";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(sc, s); }()); window._F20 = window._F20 || []; _F20.push({container: 'F20WidgetContainer', placement: '', count: 3}); _F20.push({finish: true});.....»»

Category: blogSource: valuewalkApr 8th, 2022

Strength Seen in The RealReal (REAL): Can Its 7.8% Jump Turn into More Strength?

The RealReal (REAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. The RealReal (REAL) shares ended the last trading session 7.8% higher at $8.26. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.2% loss over the past four weeks.Shares of RealReal have been getting a boost from the company’s solid operations, which are largely backed by its focus on technological innovation. The company recently released strong fourth-quarter 2021 results, wherein management stated that its technology innovations have been helping the company enhance unit economics; scale business and drive greater selling prices. Management also stated that it expects a robust 2022 performance. During the fourth quarter of 2021, the company witnessed solid top-line advancement as well as lower operating expenses across all major areas of the business.This online luxury consignment site is expected to post quarterly loss of $0.51 per share in its upcoming report, which represents a year-over-year change of -4.1%. Revenues are expected to be $138.33 million, up 40% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For The RealReal, the consensus EPS estimate for the quarter has been revised 35.6% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on REAL going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>The RealReal belongs to the Zacks Consumer Products - Discretionary industry. Another stock from the same industry, Central Garden (CENT), closed the last trading session 0.8% higher at $46.72. Over the past month, CENT has returned -0.2%.For Central Garden, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.18. This represents a change of -10.6% from what the company reported a year ago. Central Garden currently has a Zacks Rank of #2 (Buy). Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The RealReal, Inc. (REAL): Free Stock Analysis Report Central Garden & Pet Company (CENT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMar 21st, 2022

Embraer"s (ERJ) Arm Announces Partnership With Falko for eVTOL

Embraer S.A.'s (ERJ) subsidiary, Eve UAM, LLC (EVE), unveils a potential agreement with Falko involving the delivery of 200 eVTOL. This provides an opportunity for Embraer to capitalize on the growing eVTOL trend. Embraer S.A.’s ERJ subsidiary, Eve UAM, LLC (EVE), recently revealed a Letter of Intent that mentions a possible order of 200 of Eve’s electric vertical take-off and landing aircraft (eVTOL). The order has been awarded by an aircraft leasing company, Falko Regional Aircraft Limited (Falko). The Letter of Intent also entails a commercial partnership that emphasizes the development of the global network of eVTOL operators in a bid to support Urban Air Mobility ("UAM") missions.Benefits of the PartnershipUAM is an evolving aviation market that emphasizes transforming mobility around metropolitan areas through a network of efficient air transportation systems for passengers and cargo. Through eVTOL, Embraer aims to offer a safe, accessible and eco-friendly air mobility ecosystem, thus capitalizing on the emerging trend.Falko is a global leader in commercial regional aircraft leasing with a primary focus on growing regional aircraft sector opportunities. The proposed partnership brightens Embraer’s prospects in the UAM marketplace. Also, Falko’s global footprint, with a presence in the United Kingdom, Ireland and Singapore, provides Embraer an opportunity to expand in the global UAM market.Considering Embraer’s excellence in manufacturing eVTOL aircraft and an anticipated rise in demand for eVTOL globally to support zero-emissions target, the company may clinch more such agreements going forward. Such transactions are expected to bolster ERJ’s revenues from the eVTOL aircraft line of business.eVTOL’s Growth ProspectsThe rising congestion in traffic in the metropolitan areas and the need for Urban air taxis are projected to drive demand for eVTOL aircraft in a bid to make commuting easy within the cities. Per the report from the Markets and Markets firm, the global market for eVTOL aircraft is anticipated to witness a CAGR of 15.3% during the 2021-2030 period.Such growth projections provide ample prospects for companies like Embraer to capitalize and prosper in the emerging trend. Aerospace majors who boast the potential to benefit from the growing eVTOL aircraft market are Airbus SE EADSY and Textron TXT.Airbus’ CityAirbus NextGen is an all-electric, four-seat vertical take-off and landing eVTOL multicopter concept featuring a wing. It boasts an 80-km range and a cruise speed of 120 km/h, which makes it perfect for zero-emission flight operations for a variety of applications in major cities.Airbus’ average earnings surprise for the last two quarters was 69.70%. EADSY stock has rallied 21.5% in the past year.Textron’s business segment, Bell, is working on the plans to launch an eVTOL, Bell Nexus. Bell Nexus 4EX is a four-duct vehicle, which is configurable in an electric or hybrid-electric platform. With a hybrid platform, Nexus 4EX promises an extended reach to travel farther or to more remote locations based on mobility needs.Textron has a trailing four-quarter earnings surprise of 27.89%, on average. Shares of TXT have appreciated 53.8% in the past year.Price PerformanceShares of Embraer have rallied 139.6% in the past year against the industry’s decline of 28.3%.Image Source: Zacks Investment ResearchZacks RankEmbraer currently carries a Zacks Rank #4 (Sell). A better-ranked stock from the same sector is Elbit Systems ESLT, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Over the past four quarters, Elbit Systems has surpassed the Zacks Consensus Estimate, with an average surprise of 25.86%. The Zacks Consensus Estimate for Elbit Systems’ 2022 earnings has improved 2.2% over the past 60 days.Also, the Zacks Consensus Estimate for ESLT’s 2022 sales is expected to deliver growth of 3.7% from the prior-year estimated figure. Its shares have returned 29.2% to its investors in the past year. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report EmbraerEmpresa Brasileira de Aeronautica (ERJ): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Elbit Systems Ltd. (ESLT): Free Stock Analysis Report Airbus Group (EADSY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksJan 13th, 2022

U.S. Steel (X) Chooses Osceola for Advanced Steelmaking Facility

U.S. Steel's (X) site is designed to bring together the most advanced technology to form the steel mill of the future, which provides profitable solutions for its customers. United States Steel Corporation X announced that its next-generation highly sustainable and technologically advanced steel mill will be sited in Osceola, AR. It will be near U. S. Steel’s cutting-edge Big River Steel plant. The site is designed to bring together the most advanced technology to form the steel mill of the future, which provides profitable solutions for its customers.The new mill is engineered to increase the company’s customer advantages as it plots a bold path toward a more sustainable future. The optimized steel production facility is projected to mark two electric arc furnaces (EAFs) with 3 million tons annually of advanced steelmaking capability, a state-of-the-art endless casting and rolling line and advanced finishing capabilities. This first use of endless casting and rolling technology in the United States brings considerable energy, efficiency and capability enhancements to U.S. Steel’s operations.This project will apply to become LEED certified upon completion. The site selection is subject to several factors, including final agreements with key partners. The permitting for the project is ongoing and U.S. Steel looks to break ground in the first quarter of this year, with project completion and full operation anticipated in 2024.The new steelmaking facility, once completed, in combination with Big River Steel will create a 6.3 million ton mega mill, skilled to deliver many of the most advanced and sustainable steels in North America.Shares of U.S. Steel have gained 7.9% in the past year compared with a 31.4% rise of the industry.Image Source: Zacks Investment ResearchThe company, last month, announced its fourth-quarter outlook. Adjusted EBITDA for the quarter is forecast to be roughly $1.65 billion.The company’s Flat-rolled segment is projected to deliver adjusted EBITDA approaching $1 billion in the fourth quarter and EBITDA margins near the third-quarter record levels.The Mini Mill segment is expected to continue delivering EBITDA margins similar to the third quarter’s record performance regardless of lower volumes due to cautious seasonal buying, reflecting the high-quality earnings in the Mini Mill segment.The company expects the European segment to deliver lower EBITDA than the third quarter’s record performance, impacted by lower steel prices, unfavorable currency impacts and higher planned outage. The Tubular segment is projected to deliver improved EBITDA performance compared with the previous quarter on higher steel selling prices.Zacks Rank & Key PicksU.S. Steel currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks worth considering in the basic materials space are Albemarle Corporation ALB, Commercial Metals Company CMC and AdvanSix Inc. ASIX.Albemarle, currently carrying a Zacks Rank #2 (Buy), has an expected earnings growth rate of 49.6% for the current year. The Zacks Consensus Estimate for ALB's current-year earnings has been revised 9.2% upward in the past 60 days. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.Albemarle beat the Zacks Consensus Estimate for earnings in each of the trailing four quarters, the average being 22.1%. ALB has rallied around 33.5% in a year.Commercial Metals, flaunting a Zacks Rank #1, has a projected earnings growth rate of 10.5% for the current fiscal year. CMC's consensus estimate for the current fiscal year has been revised 6.6% upward in the past 60 days.Commercial Metals beat the Zacks Consensus Estimate for earnings in three of the last four quarters while missing it once. It delivered a trailing four-quarter earnings surprise of roughly 13.1%, on average. CMC has rallied around 63% in a year.AdvanSix has a projected earnings growth rate of 3.9% for the current year. The Zacks Consensus Estimate for ASIX’s earnings for the current year has been revised 1.6% upward in the past 60 days.AdvanSix beat the Zacks Consensus Estimate for earnings in each of the trailing four quarters, the average being 46.9%. ASIX has rallied 100% in a year. It currently carries a Zacks Rank #1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United States Steel Corporation (X): Free Stock Analysis Report Albemarle Corporation (ALB): Free Stock Analysis Report Commercial Metals Company (CMC): Free Stock Analysis Report AdvanSix (ASIX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksJan 13th, 2022

Enbridge (ENB) Surges 19.4% in the Past Year: Any Upside Left?

With a significant portion of its assets contracted by shippers for the long term, Enbridge???s (ENB) business model is less exposed to volatility in oil and gas prices due to the coronavirus pandemic. Shares of EnbridgeInc. ENB have jumped 19.4% in the past year compared with the 13.8% gain of the composite stocks belonging to the industry. The Zacks Consensus Estimate for Enbridge’s earnings per share for 2021 and 2022 suggests year-over-year growth of 23.2% and 9.7%, respectively.Image Source: Zacks Investment ResearchLet’s delve into the factors behind the stock’s price appreciation.What’s Favoring the Stock?Currently carrying a Zacks Rank #3 (Hold), Enbridge has an extensive network of pipeline assets responsible for transporting roughly 25% of North American crude oil production. The midstream properties are also responsible for carrying as much as 20% of the natural gas Americans consume. In Ontario and Quebec, Enbridge is dedicatedly serving 3.8 million retail customers through its Gas Distribution and Storage operations.  With a significant portion of its assets being contracted by shippers for the long term, its business model is less exposed to volatility in oil and gas prices due to the coronavirus pandemic. Underpinned by long-term contracts, Enbridge’s business model also has lower volume risk exposure.ENB has roughly placed into service C$10-billion growth capital projects in 2021. Enbridge is expecting significant growth in free cashflows in 2022, backed by these project backlogs.For 2022, Enbridge is projecting EBITDA in the band of C$15 to C$15.6 billion and distributable cash flow (DCF) per share in the range of C$5.2 to C$5.5. The metrics for this year thus suggest an improvement as compared to last year. By 2024, Enbridge expects average annual DCF per share growth of 5% to 7%.Enbridge has a strong commitment toward returning capital to shareholders. It has raised its quarterly dividend by 3% to 86 Canadian cents per share. Thus, Enbridge has increased its 2022 dividend (C$3.44 annualized), thereby marking a dividend increase for 27 straight years. Enbridge also intends to establish a share buyback program through which it will be able to repurchase C$1.5 billion of outstanding shares.Overall, the attractive financial outlook establishes the fact that Enbridge’s business model is robust with minimal exposure to coronavirus-induced commodity price volatility and volume risks.Considering these positive factors, it seems a lot of room is left for Enbridge to witness further price appreciation.Stocks to ConsiderBetter-ranked players in the energy space include Murphy USA Inc. MUSA, The Williams Companies Inc WMB and MPLX LP MPLX. While Murphy USA and The Williams Companies sport a Zacks Rank #1 (Strong Buy), MPLX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Murphy USA is well-positioned to gain from improving gasoline demand in the coming months since it is a prominent retailer of gasoline and convenience merchandise. Having a network of retail gasoline and convenience stores in 27 states, Murphy USA is being able to serve an estimated two million customers every day.Over the past 30 days, Murphy USA has witnessed upward earnings estimate revisions for 2021 and 2022, respectively.The Williams Companies is well poised to capitalize on mounting demand for clean energy since it is engaged in transporting, storing, gathering and processing natural gas and natural gas liquids.With its pipeline networks spread across more than 30,000 miles, The Williams Companies connects premium basins in the United States to the key market. WMB’s assets can fulfill 30% of the nation’s natural gas consumption, utilized for heating purposes and clean-energy generation.MPLX LP generates stable cashflows and has lower exposure to commodity price volatility since it operates midstream energy infrastructure and logistics assets. MPLX LP also generates cashflows from the fuels distribution business.Over the past 60 days, MPLX LP has witnessed upward earnings estimate revisions for 2021 and 2022, respectively. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Williams Companies, Inc. The (WMB): Free Stock Analysis Report Enbridge Inc (ENB): Free Stock Analysis Report Murphy USA Inc. (MUSA): Free Stock Analysis Report MPLX LP (MPLX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksJan 13th, 2022

ExxonMobil (XOM) Announces Buyout of 49.9% Stake in Biojet AS

ExxonMobil (XOM) will be able to purchase about 3 million barrels per year of biofuel. Exxon Mobil Corporation XOM announced that it is acquiring a 49.9% stake in Biojet AS as part of its plans to increase spending in low-carbon businesses.Biojet AS is a Norwegian biofuel company, which aims to transform forestry and wood-based construction waste into low-carbon biofuel. Biojet AS intends to build up to five facilities to produce biofuel and biofuel components. The commercial production is expected to start in 2025 at a manufacturing facility, which is to be developed in Norway.Since biofuel burns faster and cleaner than fossil fuels, ExxonMobil is growing its interest in the fuel to reduce emissions in the transportation sector. Biofuel can help reduce life-cycle greenhouse gas emissions by 85%.Per the terms of the agreement, ExxonMobil will be able to purchase about 3 million barrels per year of biofuel. The fuel can be used for passenger vehicles and heavy trucks. For marine transportation and aviation, fresh opportunities may develop as the demand and production of low-emission biofuel are expanding globally.Acquiring stakes in Biojet AS boosts ExxonMobil's initiatives to provide low-carbon fuel products to the transportation sector. With the acquisition, ExxonMobil moves a step closer to producing 40,000 barrels per day of low-emission fuel by 2025. The company can efficiently deliver biofuel to Norway and countries throughout northwest Europe by utilizing its Slagen terminal.Energy companies have been under immense pressure due to the growing urgency from investors and environmentalists to curb climate change. XOM plans to cut emissions of greenhouse gases across its operations as well as increase investments in businesses related to low-carbon solutions.Company Profile & Price PerformanceHeadquartered in Irving, TX, ExxonMobil is one of the leading integrated energy companies in the world.Shares of ExxonMobil have outperformed the industry in the past six months. The XOM stock has gained 20.6% compared with the industry’s 18.4% growth. Image Source: Zacks Investment Research Zacks Rank & Other Key PicksExxonMobil currently flaunts a Zack Rank #1 (Strong Buy).Investors interested in the energy sector might look at the following companies that presently sport a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.TotalEnergies SE TTE has one of the best production growth profiles among the oil super majors, characterized by an upstream portfolio, with above industry-average exposure to the faster-growing hydrocarbon-producing regions of the world. TTE is making regular investments to expand the renewable operation and strives to achieve net-zero emission by 2050.TotalEnergies currently has a Zacks Style Score of A for Value and B for Growth. The company manages long-term debt quite efficiently and tries to maintain the same at manageable levels. TotalEnergies’ debt to capital has been declining in the past few years.The Williams Companies, Inc. WMB, based in Oklahoma, is a premier energy infrastructure provider in North America. The company’s core operations include finding, producing, gathering, processing, and transporting natural gas and natural gas liquids.Williams Companies' debt maturity profile is in good shape, with its $4.5-billion revolver maturing in 2023. Williams is also paying its shareholders an attractive dividend, yielding nearly 6%. Beside these, the company's board recently approved a share repurchase program worth $1.5 billion, highlighting its commitment to shareholders.Murphy USA Inc. MUSA, based in El Dorado, AR, is a leading independent retailer of motor fuel and convenience merchandise in the United States. MUSA’s unique high-volume, low-cost business model helps it retain high profitability, even in the fiercely competitive retail environment.Murphy USA is committed to returning excess cash to shareholders through continued share buyback programs. As part of this initiative, the fuel retailer recently approved a repurchase authorization of up to $1 billion, which will commence once the existing $500-million authorization expires and be completed by Dec 31, 2026. The move underscores MUSA’s sound financial position and commitment to rewarding shareholders. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Williams Companies, Inc. The (WMB): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report Murphy USA Inc. (MUSA): Free Stock Analysis Report TotalEnergies SE Sponsored ADR (TTE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksJan 13th, 2022

MoneyGram (MGI) Shares Jump 4.5% on Japanese Smiles Deal

MoneyGram International's (MGI) deal with Digital Wallet Corporation to enable Smiles wallet users to leverage MoneyGram's extensive network globally. MoneyGram International, Inc.’s MGI shares jumped 4.5% yesterday after it announced a partnership with global fintech company Digital Wallet Corporation of Japan, the owner of Smiles Mobile Remittance. The deal has expanded MoneyGram’s cross-border money transfer business.The move enables clients in Japan to use the Smiles mobile app to send money to more than 200 countries. The mobile money transfer platform and digital wallet will enhance MoneyGram’s capabilities, thus boosting its international exposure. The deal will enable Smiles wallet users to leverage MoneyGram’s extensive network globally.MoneyGram, a leader in digital peer-to-peer payment evolution, expects to generate significant revenues from processing large payment volumes in the coming days via partnerships with fintech companies. The company made multiple deals with such fintech companies in recent times. It expanded the mobile wallet network in Asia by joining forces with Bangladesh's mobile financial service provider, bKash. MoneyGram joined forces with Saudi Arabia's urpay to boost its presence in the Middle East region.Through the partnership with Digital Wallet Corporation, MGI is expected to capitalize on the growing cross-border money transfer services market in the Asia-Pacific. More new deals in neighboring countries can be expected from the company in the near future, further boosting its footprint in the region. This positions the company for long-term growth.MoneyGram’s total digital transactions through the MoneyGram platform hit an all-time high in third-quarter 2021, reflecting growth of 63% from the prior-year period. The latest deal with Digital Wallet is likely to stimulate the growth momentum. Given the stiff competition prevalent in the U.S market, the company’s focus on diversifying its revenue mix geographically to align with the global remittance market growth rate bodes well.CompetitionMoneyGram is facing steep competition from peers like The Western Union Company WU, which joined forces with Cebuana Lhuillier in a bid to expand digital money transfer services across the Philippines in early September. Western Union is rapidly investing in the digital platform to stay ahead in the fast-changing remittance market. The company anticipates constant-currency revenue growth of 3-4% for 2021. The metric marked a 3% decline in 2020. WU expects operating margin to remain at 21.5% for 2021, indicating an increase from 20.8% in 2020.The remittance space is also witnessing movements from fintech players like PayPal Holdings, Inc. PYPL. PayPal offers domestic and international person-to-person payment facilities with the help of PayPal and Xoom products. The company continues to gain solid traction in the global online payment market. In the Asia-Pacific region, PYPL is expanding its presence via growing operations in Australia, Philippines and other countries. It enables customers to send payments in more than 200 markets globally. For 2021, PayPal anticipates revenues between $25.3 billion and $25.4 billion, indicating growth of 18% at current spot rates and 17% on a currency-neutral basis.Price PerformanceMoneyGram’s shares have risen 21.8% in the past year compared with a 14.5% increase of the industry.Image Source: Zacks Investment ResearchZacks Rank & Key PickMoneyGram currently has a Zacks Rank #3 (Hold). A better-ranked player in the Finance space is Alerus Financial Corporation ALRS, which presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Based in Grand Forks, ND, Alerus Financial provides numerous financial services to clients. Its financial strength is reflected by massive total assets of $3.2 billion at third quarter-end, which increased 5.4% for the first nine months of 2021. Rising investment securities are likely to keep boosting the company’s asset position in the coming quarters. Alerus Financial’s bottom line for 2021 is expected to jump 11.1% year over year to $2.80 per share. ALRS beat earnings estimates thrice in the last four quarters and missed once, with the average surprise being 23.6%. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MoneyGram International Inc. (MGI): Free Stock Analysis Report The Western Union Company (WU): Free Stock Analysis Report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Alerus Financial (ALRS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksJan 13th, 2022

CDW is a Solid Bet for Investors: Here are the Reasons Why

Growth across customer end markets, broad-based product and solutions portfolio and a healthy IT spending environment make CDW an attractive bet. Shares of CDW Corporation CDW have soared 48.6% compared with the industry’s growth of 0.9% in the past year. The company is gaining from an improved operating margin, lower interest expenses and a reduction in the effective tax rate. It is witnessing strong demand for products that enable remote working and operations continuity plans.Image Source: Zacks Investment ResearchEarnings estimates for the current and next fiscal have increased 0.3% and 1.4%, respectively, in the past two months. With impressive growth potential and robust fundamentals, this Zacks Rank #2 (Buy) integrated information technology solutions provider is an enticing investment option at the moment. CDW pulled off a trailing four-quarter earnings surprise of 12.2%, on average.Key DriversHeadquartered in Lincolnshire, IL, CDW is a leading provider of IT solutions to small, medium and large business, government and healthcare customers based in the United States, the United Kingdom and Canada. Its solutions are delivered in physical, virtual and cloud-based environments through more than 6,000 customer-facing coworkers, including sellers and highly-skilled technology specialists.CDW has four operating segments, namely Corporate, Small Business, Public and Other. It offers discrete hardware and software products to integrated IT solutions businesses such as mobility, security, data center optimization, virtualization and collaboration. Its hardware products include network communications, video monitors, enterprise and data storage. Software products are application suites, security, virtualization, operating systems and network management.The company also delivers services such as warranties, managed services, consulting design and implementation. With growth across customer end markets, CDW is benefiting from the ongoing digital transformation and coronavirus-led work-from-home wave. It is registering strong revenue growth in product categories, including collaboration tools and enterprise storage. It is worth mentioning that the company is witnessing earnings growth at a faster rate, courtesy of its share repurchase initiatives.Moreover, CDW’s robust product portfolio and frequent product refreshes act as tailwinds. Backed by a healthy IT spending environment, the company has been expanding its solutions suite and services capabilities to cater to the accretive requirements of customers. Solid demand for consumer devices like notebooks and chromebooks plus servers is an upside for the company. Growth in software and services is also proving quite beneficial for CDW.When it comes to accelerating its organic growth, the company is focused on strategic acquisitions. Recently, it acquired Amplified IT, a Google Premium education partner. Further, the buyout of Scalar Decisions in January 2019 has broadened CDW Canada’s solutions portfolio, deepened technical skillset and extended its geographic reach. The buyout of Kelway TopCo (later rebranded it to CDW UK) in August 2015 improved its ability to provide IT solutions for U.S.-based customers. CDW believes that its addressable markets in the United States, the United Kingdom and Canada represent more than $325 billion in annual sales.Other Stocks to ConsiderEndava plc DAVA is another top-ranked stock in the industry, sporting a Zacks Rank #1 (Strong Buy). The consensus estimate for current-year earnings has been revised 6.8% upward in the past 60 days. You can see the complete list of today’s Zacks #1 Rank stocks here.Endava delivered a trailing four-quarter earnings surprise of 15.2%, on average. The stock has returned 71% in the past year.ASGN Incorporated ASGN carries a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has been revised 3.3% upward in the past 90 days.ASGN delivered a trailing four-quarter earnings surprise of 7.6%, on average. The stock has gained 33.8% in the past year.Microsoft Corporation MSFT also has a Zacks Rank #2, at present. The consensus estimate for current-year earnings has been revised 0.1% upward over the past 60 days.Microsoft delivered a trailing four-quarter earnings surprise of 14.8%, on average. The stock has rallied 46.2% in the past year. MSFT has a long-term earnings growth expectation of 12%. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Microsoft Corporation (MSFT): Free Stock Analysis Report ASGN Incorporated (ASGN): Free Stock Analysis Report CDW Corporation (CDW): Free Stock Analysis Report Endava PLC Sponsored ADR (DAVA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksJan 13th, 2022